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Medically unexplained symptoms in older adults: a combination 
of physical, psychiatric and psychological factors.
P.H Hilderink, C.E.M.  Benraad, T. J. W. van Driel, M.G.M Olde Rikkert.






The experience of somatic symptoms is a normal phenomenon in the general  population. 
Two out of three men and three out of four women report at least one medical complaint 
in the last two weeks 1. This concerns symptoms such as headache, low back pain, fatigue 
and dizziness 2.  Most people, however, do not seek medical care for these complaints 3. 
A substantial part (30-50%) of somatic symptoms presented in primary care remain 
medically unexplained 4-6. In secondary medical care these percentages are even higher 7, 8. 
Physical complaints become especially burdensome when they persist over time and when 
people persevere in seeking medical help. The burden of somatic complaints for which no 
medical explanation can be found is large. Patients often report a low quality of life and 
co-morbidity rates with anxiety and depressive disorders are high 9, 10. Furthermore, the 
absence of a medical explanation gives rise to high levels of health care consumption in search 
for an organic origin of complaints, which subsequently places patients at risk for extensive 
investigations and iatrogenic damage 11.
 Terminology 
The best term to describe physical complaints of patients with unclear aetiology is subject 
to controversy. Many different terms are used, including functional somatic symptoms, 
psychosomatic symptoms, vague symptoms, subjective health complaints, and medically 
unexplained symptoms.
We have chosen to use the term Medically Unexplained Symptoms (MUS) in this thesis 
because this term is purely descriptive, neutral, and widely used in both clinical practice and 
the scientific literature 12, 13. Nonetheless, we acknowledge that this term is still controversial, 
because it reflects dualistic thinking between body and mind and it may have a negative 
connotation as it may imply that medicine has nothing to offer for the patient 14. From a 
patient perspective, however, “medically unexplained” and “functional” symptoms seem 
to be the most acceptable terms 15-17. We define MUS as physical symptoms of which 
presence, severity or consequences cannot be explained by objectively detectable pathological 
abnormalities.
In the absence of physical abnormalities, symptoms are often assumed to arise as a 
consequence of psychological stress. This process is called somatisation in the psychological 
literature 18. In the medical literature and the Dutch multidisciplinary guideline on MUS 
and somatoform disorders, somatisation is defined as the tendency to experience and 
communicate somatic distress and somatic symptoms unaccounted for by relevant pathological 
findings, to attribute them to physical illness, and to seek medical help for them 19.  
In the Diagnostic and Statistical Manual of Mental Disorders IV-TR (DSM IV-TR), MUS are 
considered as the core criterion for a somatoform disorder. Depending on type and combinations 
12
CHAPTER 1
of symptoms, duration, intensity, and level of distress, patients suffering from MUS 
may or may not be classified as having a specific somatoform disorder like somatisation 
disorder, pain disorder, conversion disorder, hypochondriasis, undifferentiated somatoform 
disorder or somatoform disorder not otherwise specified. Thus, the key step in 
classifying MUS as a somatoform disorder according to the DSM-IV-TR remains the 
exclusion of a medical cause. This classification system of somatoform disorders has been 
criticized as the assessment of whether symptoms are medically unexplained is unreliable, 
and because the concept is based on a dualistic view between body and mind 20, 21. 
To exclude a somatic symptom on the basis of underlying physical illness or injury, a doctor 
must be consulted and a definite diagnosis must be made based on objectively detectable 
pathological abnormalities on examination or investigation. This central requirement is 
associated with significant conceptual and practical difficulties. As a result of these difficulties, 
many population-based surveys have omitted somatoform disorders, and health care planners 
have tended to ignore these disorders 14. In DSM 5, somatoform disorders have been replaced 
by somatic symptom disorders. In the criteria for somatic symptom disorder, the exclusion 
criterion of the absence of a somatic cause has been omitted and criteria on the presence of 
psychological symptoms in relationship to the somatic symptoms are required now 22.
 MUS and somatoform disorders in later life
Although the clinical impression is that MUS are common in all age groups, MUS in later life 
have received very little attention. There are several pitfalls that may contribute to this neglect 
of somatoform disorders and MUS in later life. These pitfalls are illustrated in the following 
description of  three patients who visited an outpatient clinic for older persons with MUS. 
This outpatient clinic is based on a biopsychosocial approach, which is operationalized by 




Patient A was a 75 year old widow with complaints of pain in her lower back and both 
legs since more than six months. As a result of this pain and reduced energy, she spent 
most of her time in bed. Analgesics (acetaminophen and morphine) given by her general 
practitioner did not sort any effect. Subsequently, the general practitioner suspected the 
presence of a depression and started treatment with clomipramine.  This treatment initially 
resulted in some improvement, but six months later she was referred to our outpatient MUS 
clinic, because the pain had become chronic. At that time, the pain was most burdensome 
when standing or walking, while lying down relieved the pain slightly. She was not able to walk 
a hundred metres and felt extremely tired. Her daughter stressed that her mother’s complaints 
might be related to the death of her mother’s husband, who died three years ago, as the pain in 
her mother’s legs started at that time. Physical examination by the geriatrician showed normal 
muscle strength, normal sensibility, and normal reflexes in her legs. Nonetheless, she was not 
able to walk across a line and the Romberg test was positive. She had an ataxic gait with a 
13
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forward bend posture. During the examination, the pain in her legs was located on the 
backside of her legs going down to her feet. Psychiatric examination confirmed an earlier 
depressive episode in complete remission after treatment with clomipramine. An X-ray 
examination of the lumbar spine showed multiple degenerative abnormalities and multiple 
mild and moderate dispositions between L2-L5. Although these findings were also present on 
an earlier examination one year ago, this had not led to further referral to exclude a lumbar 
stenosis. This latter diagnosis was now confirmed with a subsequent MRI examination in 
the orthopaedic outpatient clinic. Surgical decompression resolved her complaints almost 
completely.
Case B
Patient B was a 75 year old woman, who was referred to our outpatient clinic because of 
chronic bowel distress and an obsessive fixation on her defecation. Her complaints started 
about two years ago, initially with constipation and a depressed mood. She lost approximately 
10 kg weight (actual weight in the past few months was 58 kg) and had trouble falling asleep. 
Several antidepressants (venlafaxine, nortriptyline, trazodone, sertraline) had been prescribed 
in therapeutic doses for sufficiently long periods, as well as augmentation strategies with 
risperidone and lithium. All treatment steps however failed, including inpatient treatment at 
a psychiatric ward of a general hospital for one month and a day care programme for three 
days a week. The consulted gynaecologist and internist could not find any explanation for her 
somatic complaints. A trial with laxatives did not yield any positive effects. On-going fixation 
on her bowel problems hindered compliance to the psychiatric treatment and made her 
husband desperate. This finally led to referral to our MUS outpatient clinic.
During the intake assessment, we saw a woman that complained merely about her defecation, 
while she also reported gastric problems such as belching.  Psychiatric examination suggested 
a depressed mood with minimal facial expression and slowed movements. The Montgomery 
Asberg Depression Rating Scale (MADRS) score was 32, indicating a severe depression. The 
physical examination by the geriatrician did not provide any new information. We concluded 
that she suffered from a severe depression with secondary obstipation, possibly partly 
explained by antidepressant drug use. She was again clinically treated at a ward for geriatric 
psychiatry. Trazodone was switched to nortriptyline and the lithium dose was lowered in 
order to improve her slowed movement. MADRS scores declined rapidly to 8 in four weeks, 
after which she could be discharged from the hospital.
Case C
Patient C was a 65 years old woman with complaints of headache since more than six months. 
The pain was located at the left side of her head, and she feared a brain tumour. The pain had 
started a few years ago, after an acute attack of dizziness and nausea during which she vomited 
in public. Since then, she continuously suffered from headaches. Since she experienced 
syncope a few months ago, she was convinced that she had a brain tumour. As she ruminated 
the entire day about having a brain tumour, she was referred to our clinic. She had never 
14
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consulted a psychiatrist before. Her physical examination revealed no abnormalities; also the 
CT scan of her brain was completely normal. Although she was somewhat reassured by these 
findings, the headache remained. The assessment by the psychologist revealed that the pain 
had a negative impact on her sleep as well as her housekeeping and daily activities. She could 
be motivated to participate in cognitive behavioural group therapy. Six months later, she was 
completely free of headaches.
 What can we learn from these cases?
Case A illustrates the main concern of most doctors: the fear of missing a somatic cause 
of a symptom. In their initial assessments, doctors tend to overestimate the presence of 
somatic explanations for a complaint. This may lead to “false-positive somatic explanations”, 
a problem that increases in older age groups 23. Increasing diagnostic difficulties of MUS in 
later life can be explained by a higher prevalence rate of co-morbid somatic disorders. The 
presence of one or more somatic diseases as well as the use of multiple medications with 
a range of potential side-effects make it difficult to determine whether complaints can be 
attributed to these diseases and their pharmacological treatment or not 24. Furthermore, 
reference values of routine blood examinations are generally based on values found in 
non-elderly populations, which may also increase the risk to consider a symptom as 
medically explained if one or more parameters are below these reference values 25. Finally, 
ageism, by the clinician as well as the patient and his or her family may incorrectly attribute 
somatic symptoms to the process of ageing. This latter explanation has probably played a role 
in case A. The degenerative abnormalities were considered normal for her age and led to the 
decision to withhold the patient from further examinations.
Case B illustrates the narrow relationship of somatic complaints with other psychiatric 
disorders, especially depressive disorders. Psychiatric co-morbidity with anxiety and depression 
is high in MUS patients 9, 26. Moreover, in patients with established somatic disease, the 
presence of depressive symptoms is highly correlated with the number and severity of 
subjective somatic complaints 27. Nonetheless, the recognition of depression and anxiety 
in patients with somatic symptoms remains problematic in clinical practice 28. The high 
co-morbidity rates have raised doubts on clinical validity of somatoform disorders as a 
separate psychiatric disorder. This belief is further enforced by the fact that antidepressants 
are the sole pharmacological group for which the effectiveness has been proven in patients 
with somatoform disorders 29. Finally, the fact that patients with a late-life depressive disorder 
more often present with somatic symptoms compared to younger depressed patients may also 
contribute to the neglect of somatoform disorders in later life 30-32. Many old age psychiatrists 
regard MUS as a symptom or secondary phenomenon of depression. 
The case of patient C illustrates the benefit of a multidisciplinary approach and the fact that 
patients with MUS may benefit from cognitive behavioural therapy. Although the effectiveness 
of cognitive behavioural therapy has only been proven for adult patients 8, the clinical 
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experiences in older patients are promising 33. The majority of patients, however, do not 
receive adequate therapy. This may partly be explained by the difficulties medical doctors 
experience in their contacts with MUS patients 34. Referral to cognitive-behavioural therapy 
may be particularly low for older patients, because older people are less often offered 
psychological therapy in general 35. Referrals to other medical specialities increase with a 
higher age of the patient, while referrals to mental health services strongly decline beyond the 
age of 65 years 36. To date, 17% of the Dutch population is above the age of 65 years, whereas 
in Dutch psychologist practices only 7% of the patients is 60 years or above, and only 2% of 
the patients is above the age of 70 years 37. 
 Aims and outline of this thesis
MUS in later life are neglected, both in research as well as in clinical settings, including 
general practice and old age psychiatry. This has resulted in limited empirical data 38 and 
ignorance of this subject in health care planning for older persons 14. To organise better 
health care for this vulnerable group of patients, we first have to increase our knowledge on 
MUS in older persons. The aim of this thesis is to expand our knowledge about the presence, 
clinical presentation, and consequences of MUS in later life. First, information is needed on 
the prevalence of this problem in later life. So far no systematic review has been performed on 
the prevalence rates of MUS and somatoform disorders in later life. Second, the interaction 
of MUS and depression needs a more thorough investigation: are MUS in later life merely 
reflections of depression? Third, the distinction between medically unexplained and 
explained symptoms is problematic, especially in later life. Can a multidisciplinary approach 
be part of a solution for this complex problem? Finally, what are the consequences of MUS on 
the level of functioning and quality of life?
 Prevalence
What is the prevalence of MUS and somatoform disorders in later life?
In chapter 2, we aim to estimate the prevalence of MUS and somatoform disorders in the 
older population based on the available literature. More specifically, we will first estimate 
prevalence rates for MUS and somatoform disorders according to diagnostic criteria. 
Secondly, we will compare prevalence rates of MUS and somatoform disorders in older age 
groups (≥ 65 years) with those found in middle aged (50-65 years) and younger populations 
(< 50 years). 
 MUS and depression
What is the role of co-morbidity of psychiatric disorders in elderly patients with MUS?
In chapter 3, results of the pilot study in older patients with MUS referred to our outpatient 
clinic are presented. Characteristics of this convenience sample are outlined, with special 
emphasis on the relationship of MUS with co-morbid psychiatric disorders.
16
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What is the longitudinal relationship between pain and depression in the elderly?
In chapter 4, we further investigate the longitudinal relationship between pain and depression. 
Does depression predict the onset of pain, or does pain increase the risk for depression? 
We analysed the longitudinal relationship between depression and pain based on a 12-year 
longitudinal study with repeated measurements (Longitudinal Aging Study Amsterdam).
 MUS and Medically Explained Symptoms (MES)
What is the somatic disease burden in older patients with MUS? 
In chapter 5, the geriatric assessment of the pilot study is outlined and differences between 
explained, partly unexplained, and completely unexplained medically symptoms are 
described.
How do MUS and MES impact on quality of life across the lifespan?
In chapter 6, differences between medically explained (MES) and medically unexplained 
symptoms (MUS) were further analysed in order to establish whether the impact of 
symptoms on health-related quality of life differs between MUS and MES and to investigate 
if age affects this impact. Data were derived from the Prevention of Renal and Vascular End 
Stage Disease study (PREVEND).
 Summary and final discussion
In chapter 7, the results of this thesis are critically reviewed and recommendations for further 





In this thesis, three different data sets were used derived from three studies: two population 
based studies and one pilot study located at a secondary care outpatient clinic.
 Clinical sample
This sample consisted of a consecutive case series of patients aged 60 years or over who 
were referred for MUS to a multidisciplinary outpatient clinic between September 2006 and 
October 2007. This outpatient clinic was part of a secondary care, old-age psychiatric service 
of the Nijmegen Mental Health Center (currently part of ProPersona). Of the 48 patients who 
were consecutively referred for MUS, 37 patients gave informed consent to participate in 
the study. Reasons for refusal were: lack of motivation (n=4), aversion against mental health 
organization (n=2), hospitalization for an acute disease (n=2), moved (n=1), or unknown 
(n=1). One subject was excluded because of an age below 60 years. All patients underwent a 
standardized examination of a geriatrician, an old-age psychiatrist, and a clinical psychologist 
within two weeks. The geriatrician performed a full physical examination, ECG, routine 
blood chemistry, and a cognitive screening with the Mini Mental State Examination (MMSE). 
Psychiatric disorders were assessed according to the criteria of the DSM–IV-TR using the 
Mini International Neuropsychiatric Interview version 5.0.0 by an old-age psychiatrist. 
 The Longitudinal Aging Study Amsterdam (LASA)
This study is a prospective cohort study of Dutch people aged 55 to 85 years (n=3107). LASA 
started in 1992 and has been described and reported extensively elsewhere 39, 40. The general 
aim of LASA was to study the autonomy and well-being of an aging population. A randomly 
selected age- and sex-stratified sample (according to expected mortality figures) was drawn 
from the population registers of 11 municipalities in the Netherlands. The reason for this relative 
oversampling of men and older-old people (both men and women) was to compensate for 
an anticipated higher unavailability for follow-up among the older-old and men. The sample 
first took part in the cross-sectional NESTOR–living arrangements and social networks study 41 
and was later interviewed and followed up every 3 years in LASA. Of the NESTOR–living 
arrangements and social networks study sample, 81.7% of the persons also participated in 
LASA (non-response was related to age but not to sex). All interviews were tape-recorded for 
quality control purposes. 
For the study presented in this thesis, we used data up to 12 years of follow-up and 
excluded only those LASA participants in whom depressive symptoms (n=14), pain 
symptoms (n=1028), or both depressive and pain symptoms (n=37) were not evaluated at 
baseline, leaving a total study sample of 2028 participants (65.3%).
18
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 The Prevention of Renal and Vascular End Stage Disease study 
 (PREVEND)
PREVEND is a population-based cohort study investigating micro-albuminuria as a risk 
factor for renal and cardiovascular disease. The recruitment of participants is described 
elsewhere 42. All inhabitants of the city of Groningen between the ages of 28 and 75 years 
(85 421 subjects) were asked to send in a morning urine sample and to fill out a short 
questionnaire on demographics and cardiovascular history. A total of 40 856 subjects (47.8%) 
responded. After exclusion of subjects with insulin-dependent diabetes mellitus and pregnant 
women, all subjects with an elevated urinary albumin concentration of ≥10 mg/l (n=7768), 
together with a randomly selected control group with a urinary albumin concentration of 
<10 mg/l (n=3395), were invited for further investigations (total n=11 163). Finally, 8592 
subjects completed the total screening program, making up the PREVEND study cohort. 
Because the PREVEND study population was enriched for albuminuria, this oversampling 
for albuminuria was counterbalanced in the current sub study. Albuminuria-negative 
participants and a random sample of albuminuria-positive participants were combined so that 
a population representative ratio of albuminuria-positive participants was achieved. Research 
assistants handed over invitations in the 2001–2002 wave to 2554 subjects to participate in 
this sub study, for which additional psychiatric and psychosocial data were collected. Of these 
2554 subjects, 1094 (43%) completed the additional measurements. Follow-up measurements 
in the 2003–2004 wave were completed by a total of 976 participants (89% of the cohort with 
additional psychiatric and psychosocial data). This latter group was analysed with respect to 
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Prevalence of somatoform disorders and medically 
unexplained symptoms in old age populations in 
comparison with younger age groups; a systematic review.
P.H. Hilderink, R. Collard, J.G.M. Rosmalen, R.C. Oude Voshaar




Objective: To review current knowledge regarding the prevalence of somatisation problems 
in later life by level of caseness (somatoform disorders and medically unexplained symptoms, 
MUS) and to compare these rates with those in middle-aged and younger age groups.
Method: A systematic search of the literature published from 1966 onwards was conducted in 
the Pubmed and EMBASE databases.
Results: Overall 8 articles, describing a total of 7 cohorts, provided data of at least one 
prevalence rate for somatoform disorders or MUS for the middle-aged (50-65 years) or older 
age (≥65 years) group. Prevalence rates for somatoform disorders in the general population 
range from 11 to 21% in younger, 10 to 20% in the middle-aged, and 1,5 to 13% in the older 
age groups. Prevalence rates for MUS show wider ranges, of respectively 1.6 to 70 %, 2.4 to 
87%, and 4.6 to 18%, in the younger, middle, and older age groups, which could be explained 
by the use of different instruments as well as lack of consensus in defining MUS.
Conclusion: Somatoform disorders and MUS are common in later life, although the available 
data suggest that prevalence rates decline after the age of 65 years. More systematic research 
with special focus on the older population is needed to understand this age-related decline in 
prevalence rates.
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 Introduction
Medically unexplained symptoms (MUS) are physical symptoms of which presence, severity 
or consequences cannot be conclusively explained by any detectable physical disorder 1. MUS 
are common in the general population with reported prevalence rates in primary care varying 
between 25 and 50% 2-4. Within the International Classification of Diseases version 10 
(ICD-10) as well as the Diagnostic and Statistical Manual for Mental Disorders version IV 
(DSM-IV), medically unexplained symptoms are classified under the section of somatoform 
disorders. In order to meet the official criteria for any of these somatoform disorders, the 
ICD-10 places emphasis on ‘a psychological cause’ of bodily symptoms, whereas in the 
DSM-IV for most somatoform disorders a psychological cause has to be assumed and most 
emphasis is placed on the presence of significant impairment in social, occupational and/or 
other areas of functioning due to MUS. Reported prevalence rates for all forms of somatoform 
disorders together vary from 10-25% in primary care 5-9.  Whether somatization, the tendency 
to express psychological distress with somatic complaints, is more common in old age remains 
a matter of debate 10-12. 
Patients with MUS or somatoform disorder report significant decreases in quality of life, 
impairment in daily functioning, increased high health care utilisation, and often undergo 
medical examinations and treatments unnecessarily 13-15. In an adult population, MUS 
double the costs for both inpatient and outpatient health care utilisation compared to patients 
without MUS when adjusted for the presence of comorbid psychiatric and somatic disease 13. 
Moreover, the increase of health care utilisation over a follow-up period of 5 years was higher 
in MUS patients than in patients without MUS 13. Furthermore, this increase was higher than 
the increase associated with depressive disorder or anxiety disorders, disorders that are also 
associated with increased health care consumption over time 16. Increased medical consumption 
is not only problematic from an economical viewpoint, but also increases the risk of iatrogenic 
damage due to unnecessary additional diagnostic and treatment procedures or significant 
doctor’s delay (by not taking patients seriously anymore). These risks are probably even more 
relevant in later life, as older persons are frailer, have a higher a priori chance of underlying 
somatic diseases, and are more dependent on carers. 
The past decades, several psychiatric interventions for MUS and somatoform disorders 
have been proven effective 17. This optimism is tempered by the experience that numerous 
patients with MUS refuse “psychological treatment” 18. Older people may be at double risk for 
withdrawal of adequate treatment. First, older people are less often offered psychological 
therapy 19. Nevertheless, age does not seem to be a factor associated with the acceptance of 
psychological treatment for functional symptoms 18. Secondly, in case of older patients, 
physicians are often faced with somatisation in the context of chronic somatic diseases. 
Higher comorbidity rates as well as higher a priori chances of underlying physical illnesses 
as explanation for MUS in older people may caution physicians to diagnose MUS or a 
somatoform disorder 20. Therefore, data showing increased numbers of somatic explained 
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symptoms with increasing age and no or only a very weak correlation between MUS and age 
are difficult to interpret 21-23.  For example, frequent attenders, often used as a proxy for MUS, 
are more common among older persons than younger persons 24, but when corrected for all 
other significant factors, such as number of chronic diseases, age itself was not associated with 
frequent attending 23. Furthermore, prevalence studies in Dutch primary care have yielded 
inconsistent findings for older patients, showing lower rates for somatoform disorders, but 
increased prevalence rates for persistent MUS 6, 25. 
To our knowledge, only two reviews have published on somatoform disorders in the elderly 
specifically 10, 11. The review by Sheehan & Banerjee (1999) was conducted before the majority 
of epidemiological studies on the prevalence of somatoform disorder in later life have 
been published. Nevertheless, these authors concluded that somatisation disorder in itself 
is rare in the older population, but that clinically relevant somatisation occurs frequently. 
Although the authors warn to use “masked depression” as explanation for somatisation in older 
persons, they acknowledge the high comorbidity between somatoform and mood disorders. 
The importance to disentangle somatisation from pure anxiety or depression is substantiated 
by another review, not specifically focussed on older persons. It shows that having numerous 
somatic symptoms or illness worry is associated with impairment and health care utilisation 
independent of anxiety and depressive symptoms 12. A German, more recent and systematic 
review on the effect of aging on somatisation stated that ageing per se is not associated with 
an increased level of somatisation, but that the scarcity of empirical data preclude final 
conclusions 11. Both reviews identified problems caused by between-study differences in the 
definition of somatisation problems, instruments used to measure somatisation, and finally the 
setting of the research population.
The objective of the present study is to estimate the prevalence of somatisation problems in 
the older population. More specifically, we will first estimate prevalence rates according to 
the level of caseness, i.e. MUS and somatoform disorders according to DSM or ICD criteria. 
Secondly, we will compare prevalence rates of MUS and somatoform disorders in older age 
groups (≥ 65 years) with those found in middle aged (50-65 years) and younger populations 
(< 50 years).
 Methods
We performed systematic searches of the PubMed and EMBASE databases for the period 
1966 through June 2011 using the keywords: medically unexplained symptoms, somatoform 
disorder, aged, prevalence, epidemiology. If applicable to the keyword, MeSH terms were 
included and then combined with the search. 
We used the following criteria for inclusion of articles: 
• Firstly, articles had to provide prevalence rates of somatoform disorders or MUS. 
 Acknowledging the scarcity of empirical data, we did not apply a time-reference to the 
 prevalence rate, but we will report the time-reference of the included studies systematically.
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• Secondly, prevalence rates had to be described for different age categories, including at 
 least one age group above 50 years of age. We defined older persons as those aged 65 years 
 or older, as in most developed countries the chronological age 65 years coincides with 
 retirement and is generally accepted as a cut-off for defining the elderly 26. Acknowledging 
 that this definition of old age is somewhat arbitrary, we also defined a middle-aged group 
 consisting of persons aged 50-65 years as  this is a period in which many chronic physical 
 conditions start to develop. 
• Thirdly, somatoform disorders had to be classified according DSM criteria and/or ICD 
 criteria using standardized instruments. MUS are defined as physical symptoms of which 
 presence, severity or consequences can not be explained by any detectable physical 
 disorder. Acknowledging the lack of consensus for defining MUS, we did not apply 
 specific restrictions with respect to definition or classification if methods were described 
 in a reproducible manner.
• Fourthly, the study had to be conducted in the general population and/or primary care 
 setting.
We did not apply any restrictions on the language of the article. 
We performed two searches in Pubmed to identify articles about somatoform disorders and 
MUS, respectively. Using the keywords: medically unexplained symptoms, aged, prevalence 
yielded 116 hits. A second search using the keywords:  somatoform disorder, aged, prevalence 
and epidemiology yielded 117 hits. Screening of all titles resulted in further examination of 
38 abstracts and 35 full text articles, from which finally only six articles met our inclusion 
criteria. References were checked and provided two more useful articles. Repeating our 
search strategy in EMBASE did not yield any additional articles. Searches were performed 
independently by both PH and RC, where after results were compared and discussed. In case 
of disagreement RCOV was consulted for a final decision.
Statistical Methods
Although we originally intended to perform formal meta-analyses, we deemed a descriptive 
overview of the data more appropriate for the following reasons. Firstly, the number of 
articles was small. Secondly, results were heterogeneous, also after differentiating between 
somatoform disorders and MUS.
 Results
Overall eight articles, describing a total of seven cohorts, were found that met our criteria (see 
table 1). In four of these seven cohorts somatoform disorders as well as MUS were assessed. 
The prevalence data of somatoform disorders and MUS in one cohort have been described 
in separate articles 27, 28. The three other cohorts only focussed on somatoform disorders 29, 30 




Four studies provided prevalence data for persons aged 65 years or above 6, 25, 30, 31, with one 
study applying an age cut-off at 60 years 29. The age cut-off for the middle-aged persons was 
even less consistent, with three studies using a cut-off at 45 years 6, 25, 32 and four studies at 50 
years 27, 28, 31. Nevertheless, two of these former studies 6, 25 also reported prevalence data for 
those aged above 65 years or age (and were thus of interest). The other study 32 only used the 
cut-off of 45 years did not provide further differentiation regarding the higher age group.
Populations:
We found four population surveys conducted in three different countries: two papers 
described data from the same German sample (German Health Survey (GHS, n =1321), one 
about somatoform disorders and one about MUS 27, 28; another paper also described a German 
sample (n=2552) 32 , one paper described a Norwegian sample (n= 1247) 31 and finally the last 
described a French sample (n=504) 30.
Three other studies, two from the Netherlands 6, 25 (n=1046 and n=225013, respectively) and 
one American study 29 (n=224), described prevalence rates in primary care.
Used instruments:
None of the studies included in the review used a similar diagnostic procedure. The most 
important differences were 1) whether or not a screening procedure was used, 2) type of 
diagnostic instrument that was used, and 3) the time-window that was applied. 
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Five of the studies used a two-stage screening procedure. Four studies started with a 
screening questionnaire and if positive, performed a diagnostic interview for somatoform 
disorders 6, 27, 28, 31. The study of Lyness used the Center of Epidemiologic Studies Depression 
Scale (CES-D) as screening 29. All persons above the cut-off point of 21 were included and a 
random sample of persons scoring under the cut-off point, aiming to oversample the amount 
of depressive disorders. The diagnostic instruments that have been used varied from fully 
structured interviews 27-29, 31, to a semi-structured interview 6 to a self-report questionnaire 32, 
to chart-review 25 and finally to a telephonic interview 30  Even the two studies that used the 
somatoform section of the fully structured computerized Composite International Diagnostic 
Interview (CIDI) were not fully comparable by taking a different time-windows describing 
respectively 12-month 27, 28 and 6-month prevalence rates 31. One study assessed current 
somatoform disorders with a duration of at least 6 months by using the semi-structured 
Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 6. The SCAN leaves room for 
further exploration and clinical judgement by experienced mental health professionals and is 
often considered the gold standard for diagnosing psychiatric disorders. Another study used 
the Screening for Somatoform Symptoms (SOMS-7), a standardized questionnaire that asks 
for symptoms in the last seven days 32. One study used a two stage telephonic interview based 
on the classification according to DSM IV to identify somatoform disorders in the last year 30 . 
Finally, the last study used data extracted from electronic records of 225013 patients of 104 
general practices based on the International Classification of Primary Care (ICPC). This study 
focussed on chronic MUS, defined as four or more contacts for a somatic complaint, without 
a medical diagnosis in the period of a year. They argued that this definition is most close to 
clinically relevant somatoform problems 25.
 
Prevalence rates:
Table 1 shows prevalence rates for different age categories for somatoform disorders in the 
included articles. Given prevalence rates are for all different forms of somatoform 
disorders together. Prevalence rates in the general population range from 11 through 21% 
in the younger age group (below 45-50 years), 10 through 20% in the middle-aged group 
(45-50 to 60-65 years), and from 1.5 through 13% in the older age group (60-65 years or 
above). None of the studies found any differences between the younger and middle age 
groups, whereas the prevalence rate in the older age groups were consistently lower. Only one 
study found increasing prevalence rates above the age of 45 years, but this study did not report 
prevalence rates for persons aged 45-65 years and persons aged over 65 years separately 32. 
Reported prevalence rates for MUS are even more heterogeneous with highest prevalence 
rates for MUS defined as at least one symptom of mild severity in the past seven days 32 
and lowest prevalence rates for chronic persistent MUS in primary care 25.  Interestingly, the 
study reporting persistent MUS in primary care found increasing prevalence rates with age, 
i.e. 1.6% below the age of 45 years, 2.4% for the age group between 45-65 years and finally 
4.6% for those aged 65 or above 25. The age-effects in the other three studies were in line with 
those reported for somatoform disorders, i.e. no difference in prevalence rates between the 
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age groups below 50 years and between 50 and 65 years, but clearly lower prevalence rates in 
the age group above 65 years 6, 28, 31.
 Discussion
Acknowledging the scarce literature on somatoform disorders and MUS in later life, our data 
suggest that somatoform disorders and MUS are common in older populations, although 
prevalence rates are lower than in younger populations. The differences between studies can 
partly be explained by the use of different diagnostic instruments, whereas the applied 
time-window may be less important. It seems plausible that semi-structured interview methods 
are more restrictive and therefore find lower prevalence rates than questionnaires 11. 
For example, all semi-structured interviews take only symptoms into account that have led to 
health care utilization. Looking at the population surveys we included, we indeed found the 
highest prevalence rates in the study that used a questionnaire 32. The lowest prevalence rate of 
1.5%, found among American older patients in primary care by using the Structured Clinical 
Interview for DSM-IV disorders (SCID) in a sample with relative oversampling of depressive 
persons, may seem puzzling 29.  The most likely explanation is that the authors only reported 
prevalence rates for pain disorder and body dysmorphic disorder, whereas the more prevalent 
somatoform disorders like undifferentiated somatoform disorder and hypochondria were not 
assessed. A second, but less likely explanation is the inclusion in this study of patients from 
private internal medicine practices, as these patients might have had higher socio-economic 
backgrounds.
Although only four of the included studies did report prevalence rates for the age group above 
65 years, the results suggest that prevalence rates of somatoform disorders and MUS are stable 
until the age of 65 years and decrease thereafter. The only exception to this finding is the study 
concerning persistent MUS, showing increased prevalence rates above the age of 65 years 25. 
These findings are in line with studies of somatoform disorders in highly selective samples 
(that had to be excluded for the present review for this reason 33-35). Using the SCREENER 
questionnaire to screen for psychiatric disorders in a medical outpatient clinic population, 
18% of the patients below the age of 63 years had a somatoform disorder versus 11% of those 
aged above 63 years 33. A study among a later life subpopulation (above the age of 55 years) 
of families of patients with Alzheimer’s dementia or depression yielded a prevalence rate of 
5% for somatoform disorder as assessed by the CIDI 34. This is similar to later life prevalence 
rates in included studies that used the CIDI as diagnostic instrument that found a prevalence 
rate of 5% above 65 years of age 31. Nevertheless, also some lower than expected figures 
have been reported. Among long-term older benzodiazepine users who visited their general 
practitioner, a prevalence rate of 8% for somatoform disorders was found using the 
PRIME-MD questionnaire35. This seems in line with other reported findings, although among 
benzodiazepine users the expected prevalence rate would be higher 36.  
Nevertheless, two studies included in the review reported increasing prevalence rates for 
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somatoform disorders and MUS with increasing age. Both studies, however, might be biased 
by the limited ability to separate medically explained and unexplained symptoms, leading to 
an overrepresentation of somatoform complaints of which an organic cause is not excluded 11. 
The first study, only differentiating between patients under and above 45 years of age, used a 
self-report questionnaire (SOMS-7) assessing all 53 physical symptoms reported in the DSM-IV 
criteria for somatoform disorders 32. Recently, we showed that in older persons the Patient 
Health Questionnaire (PHQ-15), a screenings instrument used to establish symptoms that 
point to somatoform disorders, had a similar correlation with an index of hypochondriasis 
(Whiteley Index) as an index of the burden of underlying chronic somatic diseases (Cumulative 
Illness Rating Scale)(Benraad, et al., unpublished results) . This means the physical symptoms 
assessed by the DSM-IV might be less specific for somatoform disorders in older people, than 
in younger people. The second study used a very specific definition, which included a minimum 
of four visits a year at the GP for a somatoform complaint. This definition may have led to biased 
results, as older persons with somatoform complaints tend to be more frequent attenders than 
younger adults 24.
Why do prevalence rates for Somatoform disorders and MUS decrease in the elderly?
Current classification systems for somatoform disorders are not deemed appropriate for clinical 
use 37, 38. The formal criteria for a somatisation disorder are quite restrictive. These criteria 
may be especially restrictive for elderly 4, 39. For example, the inclusion criterion for somatization 
disorder is a presence of symptoms before onset of 30 years. Poor patient recall will bias 
and lower rates 40, 41. Overall prevalence rates of somatoform disorders may thus be lowered 
artificially, further substantiated by much higher prevalence rates for suggested abridged 
forms of somatisation disorder 12. 
Secondly, used interview methods are not validated for an elderly population, which may 
lead to lower estimated prevalence rates for somatoform disorders. Epidemiological studies 
using standardized diagnostic interviews for other mental disorders, especially depression, 
have consistently demonstrated lower current and lifetime prevalence estimates in later life 
populations compared to younger populations 42, 43. Analyses of epidemiologic data in a 
population from 25-64 years based on the Diagnostic Interview Schedule (DIS) showed that 
older people more often attributed their symptoms to a physical condition in probe questions 
designed to identify the degree to which symptoms were caused by factors other than 
psychological. It was suggested that this response was due to the fact that the complexity 
of the formalized questions exceeded the cognitive capacity. “Working memory capacity” 
appeared to be a good predictor of this response behavior, also when corrected for co-morbid 
physical conditions 44. Because working memory capacity decreases with on-going age 45, this 
effect might become more prominent among older persons. The attribution of symptoms to 
a physical condition will lead to exclusion of diagnosis of somatoform disorder and thus to 
lower established prevalence rates for somatoform disorders.  Thirdly, not only do older 
patients attribute bodily symptoms to physical disorders, older persons also have more 
co-morbid somatic disorders, which makes doctors reluctant to exclude a somatic origin of 
the complaint. We previously have reported that 50% of patients referred to our outpatient 
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clinic for MUS had a somatic disorder that partly explained their symptoms 46. Excluding 
patients with a partial, but not sufficient somatic origin of their symptoms, will lead to 
substantial lower prevalence rates. Indeed some studies reported to exclude patients in 
which there was any doubt about a somatic cause for the complaint 6. Because of confusing 
terminology for somatoform disorders within the DSM-IV with implicit mind-body dualism 
and the unreliability of assessments of MUS, the American Psychiatric Association has 
proposed to rename the chapter of somatoform disorders into ‘somatic symptom disorders’. 
The DSM-V Somatic Symptom Disorder Task Group has proposed to lump somatization 
disorder, hypochondriasis, undifferentiated somatoform disorder and pain disorder together 
in one disorder named Complex Somatic Symptom Disorder 47. This is in line with empirical 
findings showing that the number of medically explained and unexplained symptoms are 
more informative for a dimensional diagnosis of somatization than the clustering of specific 
symptoms into separate somatoform disorders or functional syndromes 48-50. As the DSM-V 
will focus more on the number of bodily symptoms, irrespective of explainability or 
unexplainability of these symptoms or their associated dysfunctional cognitions, these new 
criteria may better serve older people. A final explanation could be that in old age subsyndromal 
forms of somatoform disorders are more common than somatoform disorders meeting full 
DSM criteria. This could be similar to depressive disorders in later life, where minor depression 
is much more common than major depression 51. This latter explanation, however, cannot 
fully explain the lower prevalence rates of somatoform disorders in later life as MUS, which 
can be considered a subsyndromal somatoform disorder, also decreases with age. 
Limitations:
For proper interpretation, some limitations should be acknowledged. Firstly, empirical data 
are scarce. Therefore, we choose to apply the cut-off for our a priori chosen age-categories 
liberally in order to be able to provide a more detailed overview of the literature. Nevertheless, 
the general neglect of somatoform disorders and MUS in old age still raises the question 
whether the few studies reported can be considered representative for the community-dwelling 
elderly population. Overall prevalence rates of somatoform disorders and MUS in the 
included studies, however, were in line with the prevalence rates in studies that also including 
middle-aged (50-65 years) and/or older persons (aged > 65 years) but that did not report 
age-specific data. For example, a German study using the CIDI found an overall prevalence 
rate for any somatoform disorder of 11% in the general population (n=4181) aged from 18 
to 65 8. An Italian study of the general population (n=673) reports a prevalence of 20% for 
all somatoform disorders using a semi-structured interview by a trained interviewer 5 and a 
Spanish study in primary care (n=7936) found a prevalence of 29% using the PRIME-MD 
questionnaire 7. 
Secondly, the use of different instruments for assessing somatoform disorders limits direct 
comparison between studies. Although these limitations are also applicable to the younger 
population, research in old age psychiatry is further limited by fact that most diagnostic 
instruments for somatoform disorders are not validated for use in the elderly 44. Moreover, 
no consensus exist on the definition of MUS, whereas the criteria for somatoform disorders 
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remain also highly debated and have led to widely different solutions within research projects 
varying from the introduction of other diagnostic entities such as abridged somatisation 
disorder 52 and multi-somatoform disorder 38. 
Conclusion: 
So far, little research has focused on somatoform disorders in the elderly. The existing 
evidence shows that somatoform disorders and MUS are still common in later life, although 
the available data suggest that prevalence rates decline after the age of 65 years. To understand 
why prevalence rates decrease beyond the age of 65, more systemic research with special focus 
on the old aged population is needed.  Especially adaptation and validation of instruments to 
detect somatoform disorders in the elderly is needed for this purpose. To reveal the clinical 
relevance and natural course of subsyndromal somatoform disorders, research should focus 
on studying diversity, severity and chronicity of MUS rather than differentiating into separate 
diagnostic categories with arbitrary thresholds 53. Because of the lack of consensus on the 
definition of MUS, the prevalence rates for somatoform symptoms that do not fulfil the DSM IV 
criteria are difficult to interpret and the clinical importance of subsyndromal somatoform 
disorders remains uncertain. Suggestions for future classification should consider the 
appropriateness for old age populations. 
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Objective – To examine the somatic complaints, functional impairment and psychiatric 
co-morbidity in elderly patients with medically unexplained symptoms (MUS).
Method – A consecutive case series of 37 patients referred for MUS to a multidisciplinary, 
outpatient clinic at a secondary care mental health center in the Netherlands. All patients 
underwent a standardized examination by a geriatrician, psychiatrist and psychologist.
Results – For three patients a somatic explanation was found and in two their symptoms 
spontaneously resolved before a diagnosis could be made. Of the remaining 32 patients with 
MUS, depressive disorders were present in 18 (56%), anxiety disorders in 10 (31%) and 
substance use disorders in 6 (19%).  Compared to non-depressed patients with MUS, depressed 
patients had more severe somatic symptoms, more psychological symptoms, and more 
functional impairment.
Conclusions – As we found a high co-morbidity with other psychiatric disorders in elderly 
patients with medically unexplained symptoms, a systematic psychiatric examination should 
be part of their multidisciplinary assessment.
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 Introduction
Medically unexplained symptoms (MUS) are usually defined as physical symptoms of which 
presence, severity  or consequences cannot be explained by any detectable physical disorder 1. 
A study among general practice visitors showed that 7% of patients aged 65 years or over 
were suffering from a somatoform disorders versus 22 - 28% of those aged below 65 years 2. 
However, in older persons, the diagnosis of MUS is difficult for several reasons. First the 
increased prevalence of physical morbidity with age will lead to more pathological findings, 
for which the causal relationship with the presented symptoms has to be evaluated. Secondly, 
depressed elderly patients more often present only physical symptoms. Despite these difficulties, 
there are no age-specific DSM-IV criteria for somatoform disorders. These issues may result 
in underrecognition of somatoform disorders in elderly patients 3. 
These difficulties may be overcome by a biopsychosocial approach. For this reason, we started 
a multidisciplinary outpatient clinic for older patients with medically unexplained symptoms. 
This report presents the first results with respect to the somatic complaints, functional 
impairment and psychiatric co-morbidity. 
 Method
A consecutive case series of patients aged 60 years or over who were referred for MUS to our 
multidisciplinary outpatient clinic from September 2006 until October 2007. This outpatient 
clinic was part of a secondary care, old-age psychiatric service of the Nijmegen Mental Health 
Center.
All patients underwent a standardized examination of a geriatrician (CB), old-age psychiatrist 
(PH) and clinical psychologist (DvD) within two weeks. The geriatrician performed a full 
physical examination, ECG, routine blood chemistry and a cognitive screening with the Mini 
Mental State Examination (MMSE). Psychiatric disorders were assessed according to the 
criteria of the DSM–IV-TR using the Mini International Neuropsychiatric Interview version 
5.0.0 by an old-age psychiatrist (PH) in addition to observer rated psychiatric instruments 
(see below). Severity of the presenting symptom (visual analog scale (VAS) from 0, no burden, 
through 100, unbearable symptoms) and its functional limitations were assessed in a clinical 
interview by a senior clinical psychologist (DvD). 
The number and severity of somatic symptoms in the past month was assessed by the 
well-validated Patient Health Questionnaire somatic symptom severity scale (PHQ-15) 4. 
Patients had to report the burden of 15 symptoms that cover 90% of potential somatic 
symptoms found in patients with somatoform disorders, rated on a three-point scale (no, little 
or much). The item about menstrual discomfort was omitted. In an adult population, a score 
of 5, 10, and 15, is used as threshold for mild, medium, and high level of somatisation.
The impact of the MUS on the patients’ everyday living was assessed by 7 (of the originally 
15) subscales of the Sickness Impact Profile (SIP), i.e. ‘household’, ‘social interaction’, ‘sleep’, 
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‘mobility’, ‘walking’, ‘alertness’ and ‘recreation’. The SIP has been developed to measure 
behavioural limitations due to physical illness. 
General psychopathology was measured by the Symptom Checklist 90 item version (SCL-90), 
a self-report questionnaire assessing 8 domains of psychological functioning in the past 
week. The severity of depressive symptoms was measured by the observer-rated Montgomery 
Asberg Depression Rating Scale (MADRS) and the severity of hypochondriacal beliefs and 
attitudes with the Whiteley Index, a 14-item self-report questionnaire. 
 
Data are presented as absolute numbers and percentages within groups in case of nominal 
variables, and for continuous measures as means with standard deviation (SD) or median 
with interquartile ranges (IQR) for normal and non-normal distributions. Patients with and 
without depression were compared by chi-square, two-sample t-test or Mann-Whitney U-test.
 Results
Forty-eight patients were consecutively referred for MUS, of whom 37 patients gave informed 
consent. Reasons for refusal were: lack of motivation (n=4), aversion against mental health 
organization (n=2), hospitalization for an acute disease (n=2), moving homes (n=1), or 
unknown reasons (n=1). One subject was excluded because of age below 60 years.
Patients had a median age of 75 years (range 60 – 92) and 31/37 (84%) patients were female. 
Fifteen patients (41%) were married and lived with their partner; the other 22 patients lived 
alone. The mean MMSE score was 27.5 (SD=2.4).
In three patients, a somatic disorder was found that fully explained their symptoms, namely 
herpes zoster infection of the cranial nerves combined with pulmonary fibrosis (n=1), a 
cerebrovascular accident (n=1) and spinal canal stenosis (n=1). A further two patients 
reported psychosocial problems as their primary complaint. This leaves a total sample of 32 
patients, who met DSM-IV criteria for a somatoform disorder: undifferentiated somatoform 
disorder (n=16), pain disorder (n=8), hypochondriasis (n=4), somatisation disorder (n=1), 
and a combination of hypochondriasis with a pain disorder (n=3). Fifteen (47%) patients 
had pathological findings or somatic diseases that partly explained their primary somatic 
complaint.
Seventeen out of the 32 patients had symptoms for over 5 years; only one patient had symptoms 
for less than 6 months. Twenty patients reported pain as their primary symptom (head, n=6; 
whole body, n=4; abdominal, n=4; mouth, n=3; back, n=2; joints, n=1). The other primary 
complaints were shortness of breath/coughing (n=5), dizziness (n=3), and further dysarthria, 
paraesthesia, anxiety/loneliness, and fatigue. The mean VAS severity score was 75 (SD=22). 
The impact on functioning was substantial given the mean scores on the SIP sub scale for 
social interaction (17, SD=15), sleep (24, SD=20), household activities (18, SD=19), mobility 
(16, SD=20), walking (11, SD=13), alertness (28, SD=22), and recreation (29, SD=25). 
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The PHQ-15 (see table 1) showed a medium severity of somatisation with a mean total score 
of 8.7 (SD=4.1).
TABLE 1 Prevalence of somatic complaints according to the Patient Health Questionnaire   
 (PHQ-15) (n=31).
    Burden 
       Prevalence  Little  Severe 
  Symptom % (n) % (n) % (n)
 1. Abdominal pain 35 (11) 23 (7) 13 (4)
 2. Back pain 61 (19) 32 (10) 29 (9)
 3. Joint pain 75 (23) 35 (11) 39 (12)
 4. Headache 35 (11) 13 (4) 23 (7)
 5. Chest pain 35 (11) 29 (9) 6 (2)
 6. Dizziness 45 (14) 19 (6) 26 (8)
 7. Syncope 6 (2) 3 (1) 3 (1)
 8. Heart pounding 35 (11) 23 (7) 13 (4)
 9. Shortness of breath 45 (14) 19 (6) 26 (8)
 10. Sexual problems 6 (2) 3 (1) 3 (1)
 11. Intestinal problems 68 (21) 52 (16) 16 (5)
 12. Nausea 42 (13) 19 (6) 22 (7)
 13. Fatigue 52 (16) 29 (9) 23 (7)
 14. Sleeping problems 58 (18) 29 (9) 29 (9)
The mean MADRS score of 12.2 (SD=7.6) indicated mild depressive symptoms, the mean 
SCL-90 sum score of 171 (SD=46) a moderate level of overall psychopathology, and the mean 
Whiteley Index of 5.8 (SD=3.9) a moderately high level of hypochondriacal beliefs.
Twenty-two (69%) of the patients diagnosed with a somatoform disorder had one or more 
co-morbid psychiatric disorder (one, n=11; two, n=8, three, n=3). The most common group 
of co-morbid disorders were depressive disorders (n=18 (56%): major depressive disorder, 
n=13; dysthymia, n=5). Depressed patients had a significantly longer duration of psychiatric 
treatment (Mann-Whitney z= -2.22, p=.026), higher somatic symptom burden (PHQ-15: 
t= -2.99, df=30, p=.005), higher SCL-90 subscale scores (depression: t= -3.16, df=26, p=.004; 
anxiety: t= -2.48, df=26, p=.020; somatisation: t= -2.70, df=26, p=.012; insufficiency: t= -2.67 
df=26, p=.013; hostility: t= -2.55, df=26, p=.017), and more functional impairment assessed 
with the SIP (social interactions, t= -3.15, df=28, p=.004; alertness, t= -2.80, df=28, p=.009).
(see table 2) Anxiety disorders were present in 10 patients (2 patients had 2 anxiety disorders): 
generalizedanxiety disorder (n=4), social fobia (n=3), panic disorder (n=3), agoraphobia (n=1), 
specific phobia (n=1). Finally, 6 patients (19%) met criteria for substance use disorders, i.e. 
dependence of opioids (n=4), dependence of benzodiazepines (n=1), and finally dependence 
on an unknown agent (n=1).
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Table 2 Comparison of patients with and without a co-morbid mood disorder. 
      Mood disorder 
Variables  Yes (n=18) No (n=14) Statistics
 • Age (years) mean (SD) 75 (7) 75 (7) t= -.1, df=30, p=.93
 • Female sex n (%) 15 (83%) 11 (79%) x2=0.1, df=1, p=.73
 • MMSE mean (SD) 27.6 (2.6) 27.1 (2.3) t= -.5, df=27, p=.62
 • Duration of psychiatric treatment (yrs) mean (SD) 6.2 (11.1) 0.2 (0.6) Z= -2.2, p=.026
 • No. of psychotropic drugs in history mean (SD) 3.1 (2.9) 0.6 (1.4) Z= -3.4, p=.001
MUS characteristics:    
 • Duration of MUS (years) mean (SD) 14.7 (25.4) 16.6 (29.0) t=.2, df=30, p=.85
 • Intensity primary symptom (VAS) mean (SD) 81 (16) 63 (29) t= -1.8, df=18, p=.08
 • PHQ-15 sumscore mean (SD) 10.4 (3.9) 6.5 (3.5) t= -3.0 df=30, p=.005
 • Whiteley Index mean (SD) 6.8 (4.1) 4.6 (3.2) t= -1.7, df=30, p=.10
Current psychotropic drug use:    
 • Antidepressant n (%) 8 (44%) 6 (43%) x2<.1, df=1, p=.93
 • Anxiolytics n (%) 14 (78%) 8 (57% ) Fisher Exact test, p=.27
 • Antipsychotics  n (%) 1 (6%) 1 (7%) x2<.1, df=1, p=.85
 • Analgetics n (%) 8 (47%) 3 (21%) x2=2.2, df=1, p=.14
Psychological functioning:    
 • MADRS sum score mean (SD) 16.7 (7.0) 6.4 (3.4) t= -5.0, df=30, p<.001
 • SCL-90 sum score mean (SD) 198.1 (35.6) 141.8 (37.6) t= -4.0, df=25, p< .001
  o Depression mean (SD) 43.9 (13.6) 28.7 (11.7) t= -3.2, df=26, p=.004
  o Sleep mean (SD) 9.5 (3.5) 7.9 (4.1) t= -1.1, df=26, p=.29
  o Anxiety mean (SD) 25.0 (9.2) 17.3 (6.9) t= -2.5, df=26, p=.020
  o Somatisation mean (SD) 29.6 (7.5) 22.2 (7.1) t= -2.7, df=26, p=.012
  o Agorafobie mean (SD) 11.9 (5.0) 10.3 (4.6) t= -.9, df=26, p=.40
  o Insufficiency  mean (SD) 19.1 (5.6) 14.1 (3.8) t= -2.7 df=26, p=.013
  o Hostility mean (SD) 8.7 (3.2) 6.4 (0.9) t= -2.5, df=26, p=.017
  o Interpersonal sensitivity mean (SD) 28.7 (7.9) 23.5 (7.2) t= -1.8, df=26, p=.08
Impact on functioning (SIP)    
 • social interactions SIP mean (SD) 23 (16) 8 (8) t= -3.2, df=28, p=.004
 • household activities SIP mean (SD) 22 (23) 13 (12) t= -1.4, df=28, p=.17
 • sleep SIP mean (SD) 27 (17) 20 (23) t= -1.0, df=28, p=.31
 • mobility SIP mean (SD) 19 (19) 13 (22) t= -.9, df=28, p=.40
 • walking SIP mean (SD) 12 (14) 9 (13) t= -.6, df=28, p=.55
 • alertness SIP mean (SD) 37 (21) 16 (19) t= -2.8, df=28, p=.009
 • recreation SIP mean (SD) 37 (25) 20 (21) t= -1.9, df=27, p=.07
Abbreviations: SD, standard deviation; MUS, medically unexplained symptoms; VAS, visual analog scale; 
PHQ-15, Patient 
Health Questionnaire; MMSE, Mini Mental State Examination; MADRS, Montgomery Asberg Depression Rating 
Scale; SCL-90, Symptom Checklist-90 item version; SIP, Sickness Impact Profile.
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 Discussion
To our knowledge this is the first study presenting results of a standardized multidisciplinary 
examination of elderly patients suffering from MUS. The main finding of our study is the 
high prevalence of somatoform disorder with psychiatric co-morbidity of depression, anxiety 
and substance use disorders. For interpretation, several limitations should be acknowledged: 
the sample size, the multiple comparisons, the cross-sectional nature hampering causal 
interferences and lack of generalization to other levels of health care and health care systems 
by describing a secondary care, convenience sample.
Thirty-two (86%) of 37 elderly patients referred with MUS were suffering from a somatoform 
disorder. In only three patients we found a somatic reason for the complaints. This prevalence 
rate is quite low and comparable with  figures that have been reported for patients referred 
for conversion 5. As might have been expected in an elderly population, we found in almost 
half of the patients (47%) pathological findings that partly explained their primary complaint.
Pain was the most common symptom. The severity and presenting physical symptoms as 
measured with the PHQ are comparable with patients presenting MUS in primary care 6. 
In primary care, about a quarter of the patients with MUS met DSM-IV criteria for a 
somatoform disorder 7. In our study, nearly all patients met DSM-IV criteria for a somatoform 
disorder. This is most likely explained by the fact that only patients with persistent symptoms 
that sustain after the ‘wait and see’ period will be referred and that in this patient group the 
burden on patients is large enough to justify classification as a somatoform disorder. The 
finding of only one case of somatisation disorder is in accordance with the low prevalence of 
this condition in the general population.
The prevalence of psychiatric co-morbidity was high (overall 69%), particularly for depressive 
disorders (56%). Similar figures have been reported in primary care 8. Co-morbid depression 
was associated with a higher severity of the primary somatic complaint, a higher level of 
somatisation, and more functional impairments. The recognition of depression often is 
reduced by a somatic presentation and often leads to the perception of the patient as difficult 9. 
Several trials showed that antidepressant drugs are effective in adult patients with MUS. 
To what extent this effect might be mediated by the reduction of co-morbid depressive 
symptoms has not been elucidated 10. 
We conclude that identifying psychiatric co-morbidity in older patients with medically 
unexplained symptoms is highly relevant, in addition to attention for the physical causes of 
the complaints. Therefore, we strongly advocate a standardized multidisciplinary assessment 
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 CHAPTER 4
The temporal relation between pain and depression: 
Results from the Longitudinal Aging Study Amsterdam.
P. H. Hilderink,  H. Burger,  D. J. Deeg,  A. T. Beekman,  R. C. Oude Voshaar. 





Objective: Pain and depression are both common in old age,  but their (long-term) temporal 
relationship remains unknown. This study is designed to determine whether pain predicts the 
onset of depression and vice versa.
Methods: This is a prospective, population based cohort study with  12-year follow up and 
3 years intervals in the Netherlands (Longitudinal Aging Study Amsterdam). At baseline 
participants were aged 55 to 85 years (n=2028). Main measurements outcomes were incident 
depression defined as crossing the cut-off of 16 and showing a relevant change (≥5 points) 
on the Center for Epidemiological Studies – Depression scale (CESD) among non-depressed 
participants and incident pain defined as a score of 2 or higher on the pain scale of the 
5-item Nottingham Health Profile (NHP5) in pain free participants. Multiple imputation was 
adopted to estimate missing values.
Results: In non-depressed participants (n=1769), a higher level of pain was predictive of incident 
depression in multiple extended cox-regression analysis (Hazard rate [HR] = 1.13 [95% 
confidence interval [CI]= 1.05 – 1.22], p= .001) , which all remained significant after correction 
for socio-demographic characteristics , lifestyle characteristics, functional limitations and 
chronic diseases (HR=1.09 [95% CI=1.01 – 1.18], p=.035). 
In the pain-free participants (n=1420), depressive symptoms at baseline predicted incident pain 
(HR = 1.02 [95% CI: 1.01 – 1.04], p= .006)  , This depression measure did not independently 
predicted the onset of pain in the fully adjusted models. 
Conclusion: As pain precedes the onset of depression, strategies to prevent depression in chronic 
pain patients are warranted. In contrast no effects of depression on subsequent pain were 
found when adjusting for covariates. 
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 Introduction
Depression and pain are highly prevalent in older people. A comprehensive meta-analysis has 
reported prevalence rates of 1.8% for major depression, 9.8% for minor depression and 13.5% 
for clinically relevant depressive symptoms 1. Reported prevalence rates for pain among older 
people vary between 25 and 88% 2. The National UK statistics report that approximately 50% 
of older people are in some degree of pain or discomfort 3.  Cross-sectional studies report high 
comorbidity rates between pain and depression among older persons 4, 5 and the comorbidity 
rate increases with aging 6. Moderate to severe pain symptoms that impair function and/or 
are refractory to treatment, are associated with more depressive symptoms and worsened 
depression outcomes. Similarly, depression in patients with pain is associated with more 
pain complaints and higher level of impairment 7, 8. Although the direction of the association 
between pain and depression remains unclear 9, 10, a bidirectional, reciprocal association is 
most plausible. This means that the onset of either pain or depression is a factor that increases 
the likelihood of the reciprocal symptoms and/or that each syndrome is a factor that impedes 
recovery of the other. For clinical practice this is important, as it would entail that treatment 
should target both depression and pain and that systematic evaluation of pain/depressive 
symptoms is warranted in either disorder.
Longitudinal studies among older people consistently show that pain precedes depression 
and vice versa, despite the use of different and sometimes not validated measures for 
depression and/or pain 11-17. Except one population based study including 4235 people 
aged 50 years and older 14, all studies adjusted their results for functional limitations and/or 
chronic diseases. Only in two studies the identified temporal pattern between pain and 
depression disappeared after the adjustment for covariates. In the first study, the predisposition 
of pain to depression disappeared after adjustment for physical functioning and chronic 
health conditions. Nonetheless, this study was limited as it was a population-based study 
with only 241 people due to a low and probably selective, attrition rate 12. In the second study 
among 318 older patients referred to secondary health care, the predisposition of depression 
to pain already disappeared when adjusted for sociodemographic factors 16. Probably more 
relevant than these two exceptions, are the following limitions:a), the lack of control in nearly 
all studies for pharmacological treatment of depression and pain; b), the lack of control in 
nearly all studies for life-style characteristics like smoking, use of alcohol and body mass 
index (BMI) because such characteristics may point to mediating mechanisms 10; and c) 
limitations with respect to duration of follow-up or number of assessments. All studies among 
older adults were limited to a  duration of follow-up of at most 3 years 17, 18 or a maximum of 
1 or 2 follow-up measurements  11, 16. One study among people aged 25 to 75 years, of which 
only 27% (629/2324) were aged 55 years or over, applied an 8-year follow-up and found that 
pain predicted depression and vice versa 19. Nevertheless, this study was limited by only one 
follow-up measurement and neither adjusted for lifestyle characteristics nor for functional 




To overcome these problems, we have examined the temporal relation between pain and 
depression over a 12-year follow-up within the Longitudinal Aging Study Amsterdam 
(LASA). Our objectives were to examine to what extent pain in the elderly predicts the onset 
of depression and to what extent depressive symptoms in the elderly population predicts the 
onset of chronic pain when adjusted for sociodemographic characteristics, lifestyle factors, 
functional limitations and the presence of chronic diseases. 
 Method
Study design and population
This study was conducted using data from the Longitudinal Aging Study Amsterdam (LASA), 
which is a prospective cohort study of Dutch people aged 55 to 85 years (n=3107). LASA 
started in 1992, and its methods have been described in detail elsewhere 20, 21. The general 
aim of LASA was to study the autonomy and well-being of an aging population. A randomly 
selected age- and sexstratified sample (according to expected mortality figures) was drawn 
from the population registers of 11 municipalities in the Netherlands. The reason for this 
relative oversampling of men and older-old people (both men and women)  was to compensate 
 for an anticipated higher unavailability for follow-up among the older-old and men. The 
sample first took part in the cross-sectional NESTOR–living arrangements and social 
networks study 22 and was later interviewed and followed up every 3 years in LASA; 81.7% of 
the NESTOR–living arrangements and social networks study sample participated in LASA, 
with nonresponse being related to age but not to sex. All interviews were tape-recorded for 
quality control purposes. The study design was approved by the ethics committee and all 
participants provided informed consent.
For the present study, we used data up to 12 years of follow-up and excluded only those LASA 
participants in whom depressive symptoms (n=14), pain symptoms (n=1028) or both depressive 
and pain symptoms (n=37) were not evaluated at baseline, leaving a total study sample of 
2028 participants (65.3%). Of these 2028 participants, 1769 (87.2%) had no depression at 
baseline and 1420 (70.0%) had no pain at baseline. 
Because data on pain were gathered by self-administered questionnaires which participants were 
asked to fill in after the face-to-face main interview, the response on the pain questionnaire was 
relatively low. The 1028 persons with missing pain scores had significantly higher levels of 
depressive symptoms compared to persons without missing pain scores (mean (SD) CESD 
score of 9.0 (8.1) versus 7.5 (7.6), t=5.2, df=3054, p< .001), whereas the 14 persons with 
missing depression scores at baseline had significantly higher levels of pain scores compared 
to persons without missing depression scores (mean (SD) NHP5 score of 1.9 (2.1) versus 0.7 
(1.3), t=3.4, df=2040, p= .001). As shown in table 1, excluded persons because of missing 
data were significantly older,  were less often male, had more severe cognitive impairment, 
were less educated, used less often alcohol, and had more chronic diseases and functional 
impairments. 
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Table 1
Comparison of in- and excluded participants at baseline
    Included Excluded Statistics
    (n=2028) (n=1079)
 Age (years) mean (SD) 68.8 (8.5) 72.5 (8.8) t=11.3, df=3105, p< .001
 Male sex n (%) 1030 (50.8) 476 (44.1) χx2=12.6, df=1, p< .001
 Level of education n (%)   χx2=95.0, df=2, p< .001
 • Lower education or less  771 (38.1) 605 (56.3) 
 • Secondary education  993 (49.0) 377 (35.1) 
 • Higher education  261 (12.9) 92 (8.6) 
 Cognitive functioning (MMSE) mean (SD) 27.4 (2.4) 25.7 (4.2) t=-14.0, df=3089, p< .001
 Smoking (yes) n (%) 477 (24.6) 195 (26.7) x2=1.3, df=1, p= .26
 Use of alcohol n (%)   χx2=26.1, df=2, p< .001
 • No use  382 (19.8) 210 (29.0) 
 • Moderate use  1385 (71.7) 457 (63.2) 
 • Severe use  164 (8.5) 56 (7.7) 
 Body Mass Index mean (SD) 26.6 (3.9) 27.2 (4.4) t=3.3, df=2574, p= .001
 Chronic diseases n (%)   χx2=110.5, df=2, p< .001
 • None  851 (42.0) 346 (32.6) 
 • One  716 (35.3) 377 (35.6) 
 • Two or more  460 (22.7) 337 (31.8) 
 Functional limitations n (%)   χx2=153.7, df=2, p< .001
 • None  1301 (64.5) 492 (47.0) 
 • One  370 (18.4) 214 (20.5) 
 • Two  345 (17.1) 340 (32.5) 
 Use of antidepressants n (%) 40 (2.1) 11 (1.5) χx2=0.8, df=1, p= .34
 Use of analgetics n (%) 290 (15.0) 117 (16.0) χx2=0.4, df=1, p= .52
Abbreviation: MMSE, Mini-Mental State Examination; SD, standard deviation.
Depression
At all occasions, depressive symptoms were measured using the Center for Epidemiologic 
Studies Depression scale (CESD). This is a 20-item self-report scale developed to measure 
depressive symptoms in the community. Subjects were asked how often they had experienced 
each symptom during the previous week. Items were scored on a 4-point scale, ranging from 
0 (rarely or none of the time) to 3 (most of or all the time). The values of these response 
categories were reversed for the positive affect items. The total CESD score ranges from 0 to 
60. The psychometric properties of the scale were found to be good in older populations 23, 24. 
The overlap with symptoms of physical illness has been shown to be very limited in a number 
of studies 25, 26. A score of ≥16 has generally been used as indicative for clinically relevant 
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depressive symptoms 25. In LASA, the cutoff of 16 or greater had a sensitivity of 100% and a 
specificity of 88% for major depressive disorder according to DSM-IV criteria 24.
The CESD was completed every 3 years during follow-up. Incident depression was defined as 
a score of 16 or higher at one of the follow-up assessments in patients who scored less than 16 
points at baseline combined with an increase of 5 points or more compared to their baseline 
symptom score. This criterion of a minimum change of 5 points was chosen to avoid random 
fluctuations or clinically irrelevant changes of symptoms leading to a respondent being 
identified as incident depression 27. 
Pain
The pain scale was derived from a subscale of the Nottingham Health Profile (NHP5) 28. As 
described previously, the following 5 items were included: I am in pain when I am standing, 
I find it painful to change position, I am in pain when I am sitting, I am in pain when I walk, 
and I am in constant pain 17. Response categories were ‘no’ and ‘yes’. The total scale score 
ranges from 0 (low) to 5 (high). The reliability of the scale indexed by Cronbach’s alpha was 
high (α = 0.82) 17. The pain scale was completed every 3 years during follow-up. Incident pain 
was evaluated in pain free persons (NHP5 sumscore = 0) and defined as a score of 2 or higher 
at one of the follow-up assessments. A score of 2 (clinically relevant change) was chosen to avoid 
random fluctuations or clinically irrelevant changes of symptoms leading to a respondent being 
identified as incident pain. 
Covariates
Three categories of covariates were considered of interest and added block-wise to the 
regression analyses (see below). The first category included sociodemographic variables, 
medication use and cognitive functioning. The second category were life-style factors and the 
third category were chronic diseases and functional limitations. 
The first category consisted of characteristics that were considered to be potential confounders 
and included sociodemographic variables (sex, age, and level of education), medication use 
(use of antidepressants and analgetics), and cognitive functioning. The originally 9 categories 
of educational level were categorized into 3 main categories, i.e. lower education or less 
(elementary education not completed, elementary education), secondary education (lower 
vocational education, general intermediate education, general secondary education), and 
higher education (higher vocational education, college education, university education). 
Use of antidepressants and analgetics was established by asking about the use of medication 
and by visually checking all of the participants’ medications at each 3-yearly assessment. 
Cognitive functioning was measured with the Mini Mental State Examination (MMSE) 29. 
The MMSE sumscore (range 0 – 30) was included in the analyses as a continuous variable. 
Persons scoring below the cut-off of 24 points (52/2028, 2.6%) were kept in the analyses. 
The second and third category consisted of variables, which may both confound and/or 
mediate the relationship between depression and pain. 
The second category consisted of life-style factors, i.e. current smoking (yes/no), use of 
alcohol, defined as no use, severe usage (defined as 14 or more units per week for female 
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participants and 21 or more per week for male participants) and mild to moderate usage 
(those participants not scoring no alcohol or severe alcohol usage), and finally body 
mass index, calculated as weight in kilograms divided by height in meters squared. 
The third category consisted of chronic comorbid diseases and functional limitations. The 
presence of 7 chronic physical diseases was measured by self-reports based on core questions 
and branching questions in case of positive answers. The selection of chronic diseases is based 
on prevalence (the most frequently occurring somatic chronic diseases in the Netherlands; 
roughly >5.0% in the age group 55 years and older) and functional consequences, and 
included 1) chronic non-specific lung disease, 2) cardiac disease, 3) peripheral arterial 
disease, 4) diabetes mellitus, 5) cerebrovascular accident or stroke, 6) arthritis, and 7) cancer. 
In a validation study, respondents’ self-reports were compared to information obtained from 
their GPs, and proved to be sufficiently reliable 30. For this study, the presence of chronic 
diseases was indicated at three levels: no disease, 1 disease or 2 or more diseases. The number 
of functional limitations was scored with a 3-item questionnaire and scored as none, 1, or 2 
or more difficulties 31.
Analyses
Does pain predict the onset of depression? - To examine the impact of pain on the onset of 
depression, the analyses were restricted to participants without depression at baseline (CESD 
<16, n=1769). We performed Cox-regression to take the time to onset into account. All 
primary variables and covariates were checked for normality and collinearity, their associations 
with outcome variables were checked for proportionality of hazards. Collinearity  refers to 
the possibility that two covariates are highly correlated in a way that both covariates virtually 
measure largely the same construct. This has been tested by bivariate correlations between 
covariates. Proportionality of hazards refers to the assumption that the hazards are proportional 
over time. Hazard functions have thus to be multiplicatively related, or in other words their 
ratio is assumed constant over the survival time, thereby not allowing a temporal bias to 
become influential on the end point. This has been tested by plotting the cumulative hazards 
functions for each covariate (at baseline) as well as by a complementary log-log plot.
Although Cox-regression partially corrects for dropout by censoring patients at the last available 
follow-up assessment, it requires at least one follow-up assessment in order to include 
participants in the analyses. In our case 314 participants (17.8%) dropped out before the first 
follow-up assessment. Participants who dropped out (n=314) were compared to included 
participants (n=1455) significantly older (t=9.6, df=1767, p< .001), more often male (χ2=5.0, 
df=1, p= .026), had a lower level of cognitive functioning (t=-8.3, df=1763, p< .001), used less 
alcohol (χ2=11.0, df=2, p= .004), and had more chronic diseases (χ2=11.4, df=2, p= .003) and 
functional limitations (χ2=29.9, df=2, p< .001). Dropouts, however, did not differ with respect 
to severity of depressive symptoms, pain, smoking status, BMI, use of antidepressants and use 
of analgetics. Furhtermore, the frequency of missing data for covariates was on average 2.0% per 
covariate (range 0 - 6.5%). To account for missing data, we performed multiple imputation using 
the Markov chain Monte Carlo method (fully conditional specification). Under the assumption 
of missing at random, this approach addresses biases inherent in deleting patients who do not 
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provide all data, and ulitimately allows for the inclusion of a larger and more representatieve 
sample in the analyses. We created 5 imputed data sets and all variables available (CESD score, 
NHP5 score and all covariates) were included in the imputation model as recommended 32. 
No interaction terms were added to the imputation model and we used predictive mean 
matching for continuous variables. Analyses were run for each imputed dataset and the results 
were pooled using Rubin’s 33 rules to derive one single pooled parameter etimate by taking into 
consideration the variance both within and between imputations. Only these pooled results 
were presented.
In order to examine the relationship between pain and incident depression in depth, pain was 
modelled in three different ways. First, we evaluated the effects of pain at baseline based on 
the continuous NPH5 score, ignoring pain scores during follow-up. Secondly, we calculated 
the mean severity of pain symptoms as the mean NHP5 score of all observations until the 
year of incident depression or censoring divided by the total number of observations in this 
interval as a proxy for a combined pain severity-chronicity score. Third, we included pain 
(continuous NPH5 score) as a time-dependent variable to evaluate whether pain occurs just 
before the onset of depression. All models were first corrected for subsyndromal depressive 
symptoms and covariates of the first category (potential confounders), then also for covariates 
of the second category (life-style factors) and finally also for covariates of the third category, 
that is functional limitations and chronic diseases as potential confounders and/or mediators. 
Covariates that may change over over time, were included as time-dependent covariates as 
Cox-regression allows the use of time independent (age, sex, education) and time dependent 
covariates (cognitive functioning, use of antidepressants, use of analgetics, smoking, use of 
alcohol, body mass index, functional limitations, chronic diseases). 
Do depressive symptoms predict the onset of pain? – A similar set of analyses were conducted 
to examine the impact of depressive symptoms at baseline on the onset of pain. Cox-regression 
analsyes were conducted as described above, but in this case with incident pain as the 
dependent variable. First we restricted the analysis to participants without pain at baseline 
(NPH5 score = 0, n=1420). A total of 313 participants dropped out before the first follow-up 
(n=313). These dropouts were significantly older (t=11.4, df=1418, p<.001), less educated 
(x2=15.6, df=2, p<.001) had a lower level of cognitive functioning (t=9.2, df=1416, p<.001), 
higher level of depressive symptoms (t=2.4,df== 2.4, df=1418, p=.017), more often smoked 
(x2=3.9, df=1, p=.049), less often used alcohol (x2=7.3, df=2, p=.026), and had more chronic 
diseases (x2= 26.2,df=2, p<.001) and functional limitations (x2=53.0, df=1, p<.001) compared 
to included participants (n=1107). Dropouts, however, did not differ with respect to sex, 
BMI, use of antidepressants and use of analgetics. Furhtermore, the frequency of missing 
data for covariates was on average 2.0% per covariate at baseline (range 0 - 6.2%) and up to 
60.2% for body mass index at 12 years follow-up. To account for missing data, we performed a 
separate multiple imputation procedure for the subjects in this analysis using the same 
methods as described above. The imputations were done separately for both analyses as they 
address essentially different questions pertaining to different populations, i.e. those without 
baseline depression and those without baseline pain, respectively. All results presented are 
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based on the pooled results of the 5 imputed datasets.
To examine this relationship in depth, depressive symptoms were modelled in three different 
ways. First, we evaluated the effects of the severity of depressive symptoms at baseline 
based on the continuous CESD score, ignoring depressive symptom scores during follow-up. 
Secondly, we calculated the mean severity of depressive symptoms as the mean CESD score 
of all observations until the year of incident pain or censoring divided by the total number 
of observations in this interval as a proxy for a combined depression severity-chronicity 
score. Thirdly, we included the depressive symptom severity (continuous CESD score) as a 
time-dependent variable to evaluate whether an increase in depressive symptoms occurs just 
before the onset of pain. All models were first corrected for covariates of the first category 
(potential confounders), then also for covariates of the second category (life-style factors) and 
finally also for covariates of the third category, i.e. functional limitations and chronic diseases 
as potential confounders and/or mediators.
 Results
Does pain increase the incidence of depression?
To predict the development of depression we first selected non-depressed participants at 
baseline (n=1769, 87.2%). 
Of the 1769 non-depressed participants at baseline, a total of 402 (22.7%) developed depression 
during follow-up. The mean (SD) depression free duration of follow-up was 8.1 (3.6) years, 
which corresponds to an incidence rate of 28.2 per 1.000 person years. 
In unadjusted Cox-regression models, incident depression was predicted by pain at baseline 
(Hazard Rate (HR) = 1.13 [95% CI: 1.05 – 1.22], p= .001), the combined severity-chronicity 
pain score (HR= 1.21 [95% CI: 1.12 – 1.32], p<.001), and by pain as a time-dependent 
covariate (HR = 1.15 [95% CI: 1.07 – 1.24], p< .001). The Hazard Rates count for each 1 point 
increase on the NPH5 scale. As shown in table 2, these associations remained significant 
when corrected for all three categories of covariates.
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Table 2 Multivariate Cox Regression on Incident Depression
Variable                         Imputed (N=1769)
   HR (95% CI) P Value
Pain symptoms at baseline  
 • Adjusted for covariates category 1 1.05 (1.01 – 1.10) .030
 • Additionally adjusted for covariates category 2 1.08 (1.00 – 1.16) .055
 • Additionally adjusted for covariates category 3 1.09 (1.01 – 1.18) .035
Combined severity – chronicity pain level  
 • Adjusted for covariates category 1 1.13 (1.04 – 1.24) .007
 • Additionally adjusted for covariates category 2 1.14 (1.04 – 1.24) .005
 • Additionally adjusted for covariates category 3 1.17 (1.06 – 1.29) .002
Pain symptoms (continuous at separate time-points)  
 • Adjusted for covariates category 1 1.07 (0.99 – 1.16) .088
 • Additionally adjusted for covariates category 2 1.07 (0.99 – 1.16) .092
 • Additionally adjusted for covariates category 3 1.09 (1.00 – 1.19) .047
Abbreviations: HR, hazard ratio; CI, confidence interval
Covariates category 1  include age, sex, and education (baseline), as well as Mini-Mental State  
    Examination score, use of analgetics, use of antidepressants, 
    subsyndromal depressive symptoms (time-dependent).
Covariates category 2  include smoking, use of alcohol, and Body Mass Index (time-dependent)
Covariates category 3  include functional limitations and chronic diseases (time-dependent) 
Do depressive symptoms increase the incidence of pain?
To predict the development of pain, we first selected participants with no pain at baseline (n=1420, 
70.0%). 
Of the 1420 participants with no pain at baseline, a total of 346 (24.4%) developed pain 
during follow-up. The mean (SD) pain free duration of follow-up was 8.3 (3.6) years, which 
corresponds to an incidence rate of 29.3 per 1.000 person years. 
In unadjusted Cox-regression analyses, incident pain was predicted by baseline depressive 
symptoms (HR = 1.02 [95% CI: 1.01 – 1.04], p= .006) as well as the combined severity-chronicity 
score of depression (HR = 1.03 [95% CI: 1.01 – 1.05], p= .011), but not by  including depressive 
symptoms as a time-dependent covariate (HR = 1.01 [95% CI: 0.99 – 1.03], p= .160). 
The Hazard Rates count for each 1 point increase on the CESD scale.  As shown in table 3, 
the effect of depression on incident pain fully disappeared after correction for confounders.
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Table 3 Multivariate Cox Regression on Incident Pain
Variable                         Imputed (N=1420)
   HR (95% CI) P Value
Depressive symptoms at baseline  
 • Adjusted for covariates category 1 1.01 (1.00 – 1.03) .121
 • Additionally adjusted for covariates category 2 1.01 (1.00 – 1.03) .134
 • Additionally adjusted for covariates category 3 1.01 (1.00 – 1.03) .137
Combined severity – chronicity depression level  
 • Adjusted for covariates category 1 1.01 (0.99 – 1.04) .265
 • Additionally adjusted for covariates category 2 1.01 (0.99 – 1.04) .274
 • Additionally adjusted for covariates category 3 1.01 (0.99 – 1.04) .290
Depressive symptoms (continuous at separate time-points)  
 • Adjusted for covariates category 1 1.00 (0.98 – 1.03) .823
 • Additionally adjusted for covariates category 2 1.00 (0.98 – 1.03) .801
 • Additionally adjusted for covariates category 3 1.00 (0.98 – 1.03) .797
Abbreviations:  HR, hazard ratio; CI, confidence interval
Covariates category 1  include age, sex, and education (baseline), as well as Mini-Mental State  
    Examination score, use of analgetics, use of antidepressants 
    (time-dependent).
Covariates category 2  include smoking, use of alcohol, and Body Mass Index (time-dependent)
Covariates category 3  include functional limitations and chronic diseases (time-dependent) 
 
Sensitivity analysis
We checked whether the results differed from analyses based on cases with complete data only, 
i.e. n=1139 and n=987 for analyses on incident depression and incident pain, respectively. 
Similar results were obtained when predicting incident depression, whereas with respect to 
incident pain, the baseline CESD score significantly predicted incident pain when corrected 
for socio-demographic and medication use only (HR=1.01 (95% CI: 1.00 – 1.05, p= .047). 
 Discussion
Main findings
Among community-dwelling older people, pain precedes the onset of clinically relevant 
depressive symptoms. The predictive value of pain with respect to depression is a robust 
finding, as not only pain at baseline was predictive of incident depression, but also the 
combined severity-chronicity pain score as well as by taking fluctuations in pain during 
follow up into account by including pain as a time-dependent variable. In contrast to our 
hypotheses, depressive symptoms only predicted pain in the unadjusted models. 
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Comparison with previous findings
The finding that pain precedes the development of depression is consistent with earlier 
longitudinal studies with shorter durations of follow-up in humans  11, 15-17, 19 as well as with 
experimental short-term animal research in which psychological and sociodemographic 
confounders are less important 34. Our data add that this predictive value of pain for 
developping depression remains over a 12-year follow-up period when assessed at 3-yearly 
intervals in a large group of community dwelling older people. Moreover, this relation is not 
mediated by disability, and remains significant when corrected functional limitations and 
number of chronic diseases, which is consistent with earlier findings 17. 
The negative results we found with respect to the effect of depression on the development 
of pain strengthens the finding of previous studies among older people showing no effect 
of depression on the development of pain. Our findings are in line with a review that found that 
9 out of 13 studies (among younger adults) also did not find support for the predisposition of 
depression to pain 10, as well as with three studies among older persons. First, among 318 
Chinese elderly people referred to secondary care, the predictive value of depression also 
became non-significant after correction for age, sex and educational level 16. Second, a 
recent European population-based study among 4234 people aged 50 years and over, showed 
that the effect of depression on incident pain did not disappear after adjustment for 
sociodemographic factors, but did so after additional correction for baseline co-morbid 
psychopathology 11. Unfortunately, this last study did not correct for functional limitations 
and/or chronic diseases. Finally, within a highly selective community sample of 529 older 
persons suffering from osteoarthritis, depressed mood did not led to a worsening of pain 35. 
The studies among older persons that did find an effect were indeed limited to a follow-up 
duration up to 3 years 11, 13, 15 or were conducted in specific populations as middle-aged 
patients who were already suffering from musculoskeletal pain 36 or low-back pain 37 or 
limited to the development of low-back pain in the older population 13. Our 12-year follow-up 
period is probably the major difference with previous studies and unique in this field of 
research. Nevertheless, as we measured depression and pain only once every three year, we 
can not rule out that depression impacts on the development of pain at much shorter intervals. 
Such short-term effects may led to analgetic drug use, change in lifestyle behaviour or inforce 
the development of functional impairment 18, al of which could explain our negative results in 
our adjusted models. Other positive findings of depression are not focussed on the incidence 
of pain, but on worsening of existing pain 36, 37. Depression might have differential effects in 
patients with no pain compared to patients already suffering from a painfull somatic condition. 
Depression may amplify physical pain sensations due to changes in motivational-affective 
processess and cognitive-evaluative processes that can affect the processing and perception 
of noxious input. This might also lead to different results between chronic diseases that are 
rarely accompanied by pain like cerebrovascular accidents and chronic diseases that are typically 
accompanied by physical pain sensations like osteoarthritis 38. Nonetheless, motivational-affective 
and cognitive-evaluative processes of pain experience also interfere with very low or even 
absence of noxious stimuli 39. 
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Methodological considerations
Our study is unique in having a 12-year follow-up and being able to adjust for the use 
of antidepressants and analgetics as well as for lifestyle variables. Nevertheless, for proper 
interpretation some limitations have to be acknowledged. First, selective loss to follow-up 
is an inevitable consequence of a longitudinal study in the elderly 40. The selective dropout 
of patients with more pain symptoms and more severe depression in our study may have 
biased our effects. Nonetheless, completed case analyses and analyses after multiple imputation 
yielded comparable results. Nevertheless, the high number of excluded participants due to 
missing baselinedata, may limit the external generalization of our results to the more frail 
elderly. On the other hand, multiple imputation of the whole dataset, did not yield different 
results (data available on request). Second, the interval period of 3 years hampers the 
observation of more direct temporal correlations between pain and depression. Nevertheless, 
earlier studies with shorter interval periods have shown that in the elderly the presence of 
pain and depression were remarkably stable over time 18. A third potential source of bias 
is the fact that all data relied on self-report measures of depression and pain. This might 
have caused an overestimation of the associations under study. However, if data indeed were 
contaminated due to self-report assessments, it would have lessened the chance to find 
differential results as we did. Furthermore, depressive symptoms were measured with the 
CESD, a frequently used and well-validated instrument that is sensitive to change, whereas 
the NHP5 pain scale is a much lesser used and less validated instrument in pain research. 
Especially the 5 dichotomous items may have led to a less sensitive pain measure. A fourth 
potential bias factor is the disregard of treatment other than antidepressants and analgetics 
received by the participants for depression or pain. The influence of this factor, however, is 
supposed to be mild because there is evidence that a large proportion of the elderly with pain 
or depression receive no adequate treatment 41.
Conclusion / implications
The comorbidity of depression and pain places a high burden on both the society, patients 
and families who it concerns and results in less favourable outcomes for both conditions. The 
reciprocal relationship of depresion and pain over time is thus of particular of importance 
for preventive medicine. We found that chronic pain in older adults places them at risk for 
depression. This underscores the importance of early detection of depressive symptoms in 
older persons experiencing pain, because older persons in general are less inclined to seek 
emotional help 42 and rates of underrecognition of and inadequate treatment for depression 
are high 43, 44.  Further research should thus examine whether specific strategies to prevent 
depression in chronic pain patients are effective in this at risk population. A reverse pathway 
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Physical functioning in older people with somatoform 
disorders: A pilot study.
C. E.M. Benraad, P. H. Hilderink, T.J.W. van Driel, L. G. Disselhorst, 
B. Lubberink, L. van Wolferen, M. G. M. Olde Rikkert, R. C. Oude Voshaar




Objectives – The primary objective of this study was to systematically examine the physical 
functioning of older persons with somatoform disorders, as this has never been carried out 
before.  Secondly, we wanted to test our hypothesis that higher somatic disease burden in 
patients with somatoform disorders is associated with a higher level of somatisation. 
Design and Setting – Observational study of patients referred for Medically Unexplained 
Symptoms (MUS) to our outpatient Mental Health Centre for Older Adults.   The patients 
were offered a standardized, multidisciplinary diagnostic procedure, including a comprehensive 
geriatric assessment. Inter-rater reliability between two geriatricians assessing the contribution 
of somatic pathology to the main somatic symptom was assessed.
Participants – A total of 37 patients referred for MUS (mean age  75 ± 6 years). 
Measurements – Timed Up and Go Test (TUG) and Hand Grip Strength were used as measures 
for frailty; the Cumulative Index Rating Scale for Geriatrics (CIRS-G) sum score and severity 
index measured the burden of cumulative somatic morbidity. The Groningen Activity 
Rating Scale (GARS) measured functional status. The Whitely Index was used as measure for 
somatisation. 
Results – Patients’ main symptom could be completely explained by a somatic disease in 3/37 
(8%) patients (kappa between geriatricians = 0.72). A total of 32 patients met the criterion for 
a Somatoform Disorder according to DSM-IV-TR criteria, but somatic comorbidity partially 
explained the main symptom in 15/32 patients. These patients were older (p=.049), had more 
somatic co-morbidity (p=.049), a slower gait speed (TUG, p=.035), a lower hand grip strength 
(p=.050) and a lower functional status (p=0.03) compared to the 17 patients without any 
explanation for their main somatic symptom. In contrast to our hypothesis, a higher level of 
somatisation was associated with less somatic disease burden.
Conclusion - Geriatric assessment has important added value in older patients referred with 
medically unexplained symptoms, as in half of the patients symptoms can be partially or fully 
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 Introduction
Medically Unexplained Symptoms (MUS) are a common phenomenon. In primary care 15-39 
% of presented somatic symptoms remain unexplained 1,2. MUS become burdensome when 
MUS persist over time and people persevere in seeking medical help. Psychological processes 
like somatisation and hypochondriasis are thought to predispose, precipitate or perpetuate 
the persistence of MUS. Somatisation is conceptualised as a tendency to express psychological 
distress with somatic complaints. In the medical literature, somatisation is often defined 
according to Lipowski (1998) as “the tendency to experience and communicate somatic 
distress and somatic symptoms unaccounted for by relevant pathological findings, to attribute 
them to physical illness, and to seek medical help for them” 3. Hypochondriasis is an excessive 
preoccupation or worry about having a serious medical illness 4. Although hypochondriasis 
can be present without having any medical symptoms, approximately 75% of the people 
suffering from hypochondriasis also have MUS 5. In the Diagnostic and Statistical Manual 
of Mental Disorders IV-TR (DSM IV-TR), a widely used classification system for psychiatric 
disorders, MUS are considered as the core criterion for a somatoform disorder. Nonetheless, 
depending on type and combinations of symptoms, duration, intensity and level of distress, 
patients suffering from MUS may or may not meet the criteria for a specific somatoform 
disorder like somatisation disorder, pain disorder, conversion disorder, hypochondriasis, 
or somatoform disorder not otherwise specified. It is important to note that a Somatoform 
Disorder can be present when a patient has partially explained somatic symptoms: the adverse 
effects of the somatic symptoms on everyday life are substantially more severe than expected. 
The burden of MUS and Somatoform Disorders is large: patients often report a low quality 
of life and suffer from co-morbid anxiety and depressive disorders 6. Furthermore, MUS give 
rise to high levels of health care consumption in search for an organic origin of complaints, 
which places patients at risk for extensive and potentially iatrogenic investigations 2. In 10-30 
% of MUS, and 50-70 % of hypochondriasis, the condition becomes chronic 7. 
Although empirical data are scarce, prevalence rates range from 1.5% through 18% for MUS 
and from 5% through 13% for Somatoform Disorders in people aged 65 years and over 8. 
These figures are somewhat lower than those reported for younger people, which may be 
explained by diagnostic problems of MUS or Somatoform Disorders in later life.  At an older 
age, somatisation often occurs in the context of chronic somatic diseases 9, and thus more 
pathological findings have to be examined in an attempt to account for the physical 
complaints 10. Higher co-morbidity rates as well as higher a priori chances of underlying 
physical illnesses as explanation for physical complaints in older people probably cause 
physicians to consider these symptoms as explained 11.
To date, several etiological models for (the persistence of) MUS have been proposed 12-16. 
Although consensus exists on the interplay between biological, psychological and social 
elements in the aetiology of MUS, models differ in the relative contribution of these factors. 
Psychological and social processes can be a precipitating factor, but are most often assumed to 
be predisposing and perpetuating factors. Biological processes, by contrast, are only included 
as a precipitating factor. In most models, bodily sensations that give rise to somatic symptoms 
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are thought to originate from both normal physiological processes (e.g. bowel peristaltic), 
from pathophysiological processes due to sub threshold medical conditions (e.g. elevated 
blood glucose levels without actual diabetes), or from clinical diseases. The contribution of 
pathophysiological processes is also reflected by the criterion for somatoform disorders that 
complaints have to be more severe than can be explained by the underlying somatic condition. 
Further support for the contribution of these processes can be deduced from the finding 
that in depressed older adults the level of somatisation increases with the number of chronic 
somatic conditions 17.  Thus, we might expect somatisation problems to increase parallel with 
an increase in somatic diseases. Therefore, more emphasis should be placed on the physical 
functioning of patients suffering from MUS or Somatoform Disorders, particularly in later life.
The objective of the present study was 1) to describe the physical morbidity and functioning 
of a convenience sample of patients referred for MUS to an outpatient Mental Health Centre 
for Older Adults in the Netherlands and 2) to explore the association between the level of 
somatisation and physical performance. We hypothesized a positive association between a 
higher level of somatisation and  lower level of physical performance.  
 Methods
Design
All patients, aged 60 years or over, referred for MUS to an outpatient Mental Health Centre 
for Older Adults  in Nijmegen in the Netherlands between September 2006 and October 2007 
underwent a standardized examination by a geriatrician (C.B.), old-age psychiatrist (P.H.) 
and clinical psychologist (DvD) within two weeks after referral. The psychiatric characteristics 
of this cohort have been described elsewhere 18 . In short, psychiatric disorders were assessed 
 by an experienced old-age psychiatrist (P.H.) according to the criteria of the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth Edition (DSM–IV) using the Mini 
International Neuropsychiatric Interview version 5.0.0. The senior clinical psychologist 
(Dv.D.) focussed on the consequences of the somatic symptoms in everyday life, in order to 
prepare for and motivate patients for cognitive-behavioural treatment. The Whiteley Index 
(WI) was administered to assess the severity of hypochondric beliefs and attitudes as a measure 
of somatisation 4,19. This self-report questionnaire includes 14 dichotomised items (yes/no) 
related to bodily preoccupation, disease phobia and conviction of the presence of disease. The 
sum score range from 0-14, with higher scores being indicative of more severe somatisation 
levels and hypochondric beliefs. The Dutch version has been validated in different populations 
with showing good test-retest reliability (0.90) and good internal consistency (Cronbach’s α 
ranges between 0.76 and 0.80). Although a cut-off for clinically relevant levels of somatisation 
is not available, the WI appeared to discriminate reasonably well between hypochondriacal 
and non-hypochondriacal subjects 20.
Geriatric assessment
The geriatrician performed a complete geriatric assessment including an ECG, routine blood 
chemistry, somatic disease burden, activities of daily living and cognitive screening with 
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the Mini-Mental State Examination (MMSE) 21. All correspondence of previous medical 
examinations was evaluated and when relevant, previous medical specialists were consulted 
by telephone. If considered necessary, further investigations were carried out. The duration of 
the primary complaint was estimated in months and patients had to rate the current intensity 
of their primary complaint on a visual analogue scale (VAS). 
The geriatrician (C.B.) who did the geriatric assessment judged the main symptom as 
completely explained, partially explained or unexplained by an underlying somatic disease. 
As there is no objective criterion to decide whether a bodily complaint is medically explained 
or not, a second geriatrician (L.D.) also classified the patients’ symptoms according to these 
three categories. This classification was based on the medical records (including findings of 
the first geriatrician), but blind for the final judgement of the first geriatrician. Subsequently, 
discrepancies were discussed between both geriatricians in order to achieve consensus. In 
case no consensus could be reached, a third geriatrician made the final classification for that 
patient (M.O.R).
Somatic Comorbidity – The Cumulative Illness Rating Scale – Geriatric (CIRS-G) was used 
to measure cumulative burden of diagnosed somatic diseases 22. This scale was scored by 
a clinician and contains 14 domains: 13 domains of different somatic organ systems and 1 
psychiatric domain, which was left out. Each item can be scored from 0-4 (range 0-52, higher 
score: more comorbidity). In our study we used the sum score and the ‘severity index’ of the 
CIRS-G:  the total score divided by the number of domains on which the score was  > 0 23.
Frailty – As a gold standard for frailty does not exist and available frailty indices at least partly 
overlap with the criteria for psychiatric diseases 24,25, we administered two proxy measurements 
for physical frailty: the Hand Grip Strength 26, and the Timed-Up-and-Go-Test (TUG) 27. 
Hand Grip Strength was measured using the Jamar Dynamometer as the best score of two 
consecutive attempts. The TUG is a measure that scores the time needed by a  patient to get 
up from a chair, walk 3 metres, turn around, walk back to the chair and sit down again. Both 
tests have high inter-rater and test–retest reliability. 
Functional status – We used the Groningen Activity Restriction Scale (GARS) to measure 
activities of daily living 28. This self-assessment scale contains 18 items of ADL and IADL, with 
1-4 points per item, (range 18- 72; higher score: more dependent). 
Analyses 
First, we evaluated the origin of patients main symptoms. We categorised patients referred 
for MUS in those having completely explained, partially explained and unexplained medical 
symptoms. Inter-rater reliability of this classification into three categories by both geriatricians 
was estimated by calculating the kappa. 
Secondly, we compared patients suffering from somatoform disorders with partially explained 
or unexplained main symptoms with respect to physical functioning. Differences were tested 
by chi-square and by two-sample t-test or Mann-Whitney U-test. As ours was a pilot study 
and data-analysis was mainly explorative, we did not apply a Bonferroni correction and 
considered p-values of less than .05 to be significant.
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Thirdly, correlations between measures of somatisation (Whiteley Index) and measures 
of somatic disease burden (CIRS-G, GARS) and frailty (Hand Grip Strength, TUG) were 
calculated by Pearson’s correlation. Correlation coefficients .10 and .30 are considered small, 
between .30 and .50 medium and between .50 and 1.00 strong 29.
 Results
Patient characteristics
A total of 48 patients were referred for Medically Unexplained Symptoms (MUS) of which 37 
patients agreed to a diagnostic assessment. Reasons for refusal were: lack of motivation (n=4), 
aversion against mental health organization (n=2), hospitalization for an acute disease (n=2), 
age below 60 years (n=1), moved homes (n=1), unknown (n=1).
The 37 patients who went through the diagnostic procedure had a mean age of 74.8 years (SD=7.0 
years) and 31/35 (84%) patients were female. 15 Patients (41%) were married and lived with their 
partner; the other 22 patients lived alone (widowed, n=18; divorced, n=2; never married, n=2). 
The mean MMSE score was 27.5 (SD = 2.4) indicative of good cognitive functioning. 
Classification of the primary symptom
The kappa of inter-rater agreeability between the overall classification of the main somatic 
symptom as completely explained, partially explained, or unexplained by both geriatricians 
was 0.67. 
The first geriatrician (CB) classified three out of these 37 patients as having a completely 
explained main somatic symptom. The second geriatrician (LD), who blindly evaluated 
the medical records, classified these same three patients as having a somatic disorder that 
completely explained their symptoms. In addition he scored also two other patients as such. 
This resulted in a kappa of 0.72 for the comparison between completely explained versus 
partially explained/unexplained symptoms. After discussing these two patients, consensus 
was reached that the underlying somatic condition only partially explained the main symptom. 
Of the remaining 34 patients, the main symptom spontaneously resolved in two patients, 
whereas the other 32 patients all met DSM-IV-TR criteria for a Somatoform Disorder (see for 
details also Hilderink et al., 2009) 18. Among the 32 patients with a somatoform disorder, the 
kappa of inter-rater agreeability of main complaints that could be partially explained by an 
underlying somatic disorder versus those that were unexplained between the first (C.B.) and 
second (L.D.) geriatrician was 0.69. Nonetheless, consensus could quite easily been reached 
in discrepant cases when both geriatricians presented their arguments to each other. This 
consensus meeting resulted in a final classification of 15 patients with a partially explained 
and 17 with a unexplained main symptom. 
Physical functioning in somatoform disorders in later life (n=32) 
During the geriatric assessment, 20 patients reported pain as their primary symptom (head, 
n=6; whole body, n=4; abdominal, n=4; mouth, n=3; back, n=2; joints, n=1). The other 
primary complaints were shortness of breath/coughing (n=5), dizziness (n=3), and further 
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dysarthria, paraesthesia, anxiety/loneliness, and fatigue.
Table 1 presents the characteristics of all patients diagnosed with a Somatoform Disorder, 
stratified for patients with partially explained and unexplained main symptoms. The mean 
duration of the main symptom was almost 6 years in both groups. Patients in whom the 
main symptom was partially explained by a somatic condition were older (p= .049), more 
functionally impaired (GARS p=0.030), had higher chronic disease burden as measured by 
the CIRS-G total score (p=0.049), a lower gait speed (TUG p=0.035) and lower Hand Grip 
Strength (p=0.050) compared to patients with no explanation for their main symptom.  This 
latter group, however, had numerically higher levels of somatisation on the Whitely Index, 
although the difference did not reach statistical significance (p=0.068). 
Table 1 Comparison of somatic disease burden in patients suffering from somatoform 
  disorder with and without a partially explained medical symptom (n=32)
    
 Explanation for primary Statistics
 complaint
Variables  Unexplained  Partially P
     (n=17) (n=15)
  
Demographics:    
 • Age (years) mean (SD) 73.0 (6.6) 77.7 (6.2) .049
 • Female sex n (%) 13 (77) 13 (87) 0.46
MUS characteristics:    
 • Duration of MUS (months) mean (SD) 70 (71) 71 (72) 0.99
 • Intensity primary symptom (VAS) mean (SD) 7.2 (21) 7.7 (24) 0.67
Psychiatric morbidity    
 • Depressive disorder n (%) 11 (65) 7 (47) 0.31
 • Anxiety disorder n (%) 6 (35) 4 (27)  0.60
Physical functioning:    
 • CIRS total score mean (SD) 6.5 (4.2) 10.5 (6.0) .049
 • CIRS severity index mean (SD) 1.4 (0.4) 1.8 (0.6) .076
 • Grip strength mean (SD) 32.7 (13.7) 22.2 (11.5) .050
 • Timed up-and-go mean (SD) 7.9 (2.9) 11.8 (5.4) .035
 • GARS mean (SD) 23 (10) 34 (14) .030
Level of somatisation    
 • Whiteley Index mean (SD) 6.9 (4.0) 4.6 (3.4) .068
Abbreviations: MUS, medically unexplained symptoms; GARS, Groningen Activity Restriction Scale. CIRS-G: 
Cumulative Illness Rating Scale Geriatric.  VAS, visual analogue scale; SD, standard deviation; p, p-value; 
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Associations between somatisation and parameters of physical functioning
Somatisation, as indexed with the Whitely Index, had a substantial but inverse relationship 
with gait speed (TUG, r= -0.44, p=.015) and a definite, but small relationship with Hand Grip 
Strength (r=0.27, p=.16). There was also a small inverse relationship with the CIRS severity 
index (r=-0.21, p=.27) and the Groningen Activity Restriction Scale (GARS, r=-0.32, p=.078). 
We found virtually no relationship with the CIRS-G total score (r=-0.02, p=.91).
 Discussion
This is the first study on a multidisciplinary assessment of patients referred for Medically 
Unexplained Symptoms (MUS) in an older population. Our patients were suffering on average 
for 6 years with their somatic symptoms and their referring physicians referred them specifically 
for psychological treatment having finalised their somatic diagnostic work-up probably much 
earlier. Nonetheless, we showed that these patients referred to an old age psychiatry setting still 
importantly benefit from a comprehensive geriatric assessment. A small proportion (8%) of 
patients with seemingly unexplicable symptoms still could be explained, while nearly half of the 
formerly unexplained symptoms could be partially explained. 
There are several limitations inherent in such a small pilot study on a convenience sample 
referred to an old age psychiatry setting. Here we would like to address the lack of statistical 
power and the fact that the cross-sectional nature hampers firm conclusions and causal 
interferences. 
Nevertheless, although preliminary, our results are important. MUS and Somatoform Disorders 
in later life are largely neglected in geriatric literature, whereas chronic nature of the 
complaints, the physical functioning and frailty of this older age group may have considerable 
clinical consequences. 
Although referred for MUS, in three (8%) out of 37 patients in our sample there did turn 
out to be a completely somatic explanation for the main symptom. In previous studies, 
misdiagnosis of MUS has mainly been focused on misdiagnosis in conversion: in a review a 
mean percentage of 4 % misdiagnosis was found in 22 studies published since 1970 30, 31, which 
is lower than in our study. 
The overall agreement between two geriatricians judging the main symptom as completely 
explained, partially explained or unexplained was moderate to good.   We found only two 
studies on medical judgment of symptoms in these three categories. Our kappa is in line with 
these studies, which used a different methodology and were conducted in younger populations. 
In the first study, a kappa of 0.76 was found on agreement between two psychiatrists and one 
general physician using a chart review method 32. The second study, a retrospective chart 
study, reported an agreement in diagnosis of only 43% between paediatricians in a panel for 
children who were referred for unexplained chronic pain 33. 
Comparison of the groups of patients with a partially explained and unexplained main 
somatic symptom showed that the patients in the first group were significantly older, had 
more somatic co-morbidity, a lower hand grip strength, and a slower gait speed. The CIRS-G 
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total score for the group of patients with partially explained somatic complaints was comparable 
with a group of patients on an acute geriatric ward 22, but the CIRS-G ‘severity index’ was low 
and not significantly different for both groups.  This indicates that, although the number of 
somatic diseases was higher in the partially explained group, the severity of the underlying 
somatic diseases was low to moderate. Overall, the comprehensive geriatric assessment 
data indicate that the group of persons with unexplained symptoms is a strikingly healthy 
population from a somatic point of view, whereas the group of persons with partially explained 
symptoms is less healthy and more frail. Particularly this latter group may benefit from a 
multidisciplinary approach including geriatric assessment.
In contrast to our hypothesis, a higher level of somatisation was associated with a better physical 
performance. First, the strong trend towards higher level of somatisation, as measured 
with Whiteley Index, was associated with a lower degree of frailty, of which the Timed 
Up-and-Go test reached statistical significance. Second, we did not find an association with 
the CIRS-G sum score, whereas the severity index of the CIRS-G was negatively associated 
with somatisation: more somatic conditions, be it of moderate severity, was associated with 
less somatisation. 
There might be several explanations for this unexpected finding; physical problems in later 
life might result in more adequate interpretation of bodily sensations and physical problems 
might have validated people’s help-seeking behaviour and thereby have had a dampening effect 
on the level of somatisation. This also offers an alternative explanation for the decreasing 
prevalence rates of MUS and somatoform disorders with age 8.
Conclusion
A geriatric assessment has added value in diagnosing older patients referred for MUS, even 
when symptoms exists for years. In half of the patients symptoms that could not be explained 
before, proved to be partially or fully explicable following such a comprehensive assessment. 
Moreover, a high somatic disease burden was found in those patients with partially explained 
symptoms. Longitudinal research is necessary to disentangle the relationship between 
somatisation and somatic disease burden in later life as this will guide therapeutic strategies, 
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Impact of medically unexplained symptoms on health related 
quality of life: A comparison with medically explained 
symptoms and age-effects.




Objective: We aimed to clarify whether medically unexplained symptoms (MUS) cause the 
same degree reduction in health-related quality of life (HRQoL) as medically explained 
symptoms (MES). Secondary aim is to  describe the effects of aging on this impact.
Method: In a population based cohort (n=946, aged 28-75 years), MUS and MES were measured 
using the Composite International Diagnostic Interview (CIDI) and HRQoL using the 
EuroQol-5 Dimensions (EQ-5D). Using multiple linear regression, we regressed MUS, MES 
and their interaction with age on HRQoL, first adjusted for socio-demographic variables and 
subsequently adjusted for psychiatric comorbidity. In case of significant interaction terms, 
age-stratified results will be presented. 
Results: Overall the association between MUS and HRQoL was stronger (B=-.247, SE =.021, 
p<.001) than between MES and HRQoL  (B=-. 188, SE=.022, p<.001). Adjusted for psychiatric 
co-morbidity, these associations became almost equal (for MES: B=-.183, SE=.021, p<.001; 
for MUS: B=-.194, SE=.020, p<.001). Age significantly interacted with number of MUS in 
explaining variance in HRQoL, but not with the number of MES. The impact of MUS on 
HRQoL is much larger in people aged below 65 years (B=-.272, SE=.023, p<.001) versus those 
aged 65 years and over (B=-.149, SE=.046, p=.002). Only in the older age group, this association 
lost significance when adjusted for psychiatric co-morbidity (B=-.085, SE=.045, p=.062). 
Conclusion: In an adult population the impact of MUS on HRQoL is larger than the impact of 
MES. However in later life the impact of MUS decreases suggesting that older persons cope 
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 Introduction
Physical symptoms account for the majority of consultation in primary care and at least a 
third of these complaints remain medically unexplained 1. While it is recognized that physical 
symptoms are an important cause of illness burden in patients, it is not clear whether 
medically unexplained symptoms (MUS) cause the same degree of morbidity and reduction 
in health-related quality of life (HRQoL) as medically explained symptoms (MES). HRQol 
is defined as those aspects of self-perceived well-being that are related to or affected by the 
presence of disease or its treatment 2. The impact of MES and MUS on HRQoL may further 
differ across the lifespan, taken into account that the number of MES clearly increases with 
age, while no or only a very weak correlation has been found between the prevalence of MUS 
and age 3-5. 
Because of higher numbers of MES in older persons, one would expect lower HRQoL. 
Nonetheless, two-thirds of hospitalised older patients report good HRQoL. In this group, 
lower physical and psychological HRQoL was significantly associated with impaired personal 
activities of daily living, impaired cognition, depression, anxiety and a higher medication use 6. 
MUS are defined as physical symptoms of which presence, severity or consequences cannot 
be explained by any detectable physical disorder 7. Although clinicians are almost daily faced 
with MUS throughout the lifespan, almost no empirical data are available for MUS in later 
life 8. A recent review suggests that prevalence rates of MUS are stable until the age of 65 years 
and decrease thereafter 9. This might be an artefact caused by diagnostic issues differentiating 
between MES and MUS in later life as well as by conceptual difficulties. The concept of MUS 
has been criticized as it is dualistic, and its measurement is time consuming and unreliable 10, 11. 
Therefore, it has been suggested that the total number of physical symptoms, including both 
medically explained and unexplained symptoms, is more informative in estimating health 
related quality of life 12-15. Cross-sectional clinical studies indeed found a significant correlation 
between a high somatic symptom count, including both medically explained and unexplained 
symptoms, and impaired health status 1, 16. Furthermore, one prospective cohort study showed 
that total somatic symptom counts predicted impaired health status over time 17. The impact 
of MUS on the HRQoL in old age populations, however, has not been reported yet.  
In adult populations some have suggested that MES and MUS are associated with similar 
levels of disability 18, 19, while others have suggested that MUS are associated with greater 
disability 20, 21. In a Dutch primary care population, Quality of Life (QoL) of patients suffering 
from MUS was lower than that of the overall primary care population, but higher compared 
to depressed patients in primary care 21.  A proposed explanation for a differential impact on 
HRQoL between MES and MUS is the increased prevalence of affective disorders in patients 
suffering from MUS as compared to patients with MES as well as the fact that patients with 
MUS on average do have higher numbers of somatic symptoms 22. In a predominant South 
Asian primary care population, patients with MUS had significantly more physical symptoms, 
higher levels of anxiety and depression, and lower HRQoL compared with patients with MES. 
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Health-related quality of life in patients was independently predicted by occupational status, 
educational status, anxiety, depression, and the number of physical symptoms reported. 
Whether symptoms were medically explained or not did not add significantly to the model 
after adjusting for other variables 22.  
The primary aim of the present study is to examine the effect of age on the impact of MUS and 
MES on health-related quality of life. We hypothesize that 1) MUS are more strongly associated 
with impaired HRQoL than MES, 2) the differential impact of MUS and MES on HRQoL can 
be explained by an increased prevalence of psychiatric comorbidity in patients with MUS as 
compared to patients with MES, and 3) the impact of MES on HRQoL decreases with age in 




This study has been performed in a cohort derived from Prevention of Renal and Vascular 
End Stage Disease (PREVEND), a population cohort study investigating micro-albuminuria 
as a risk factor for renal and cardiovascular disease. The recruitment of participants is 
described elsewhere 23, but will be summarised below. All inhabitants of the city of Groningen 
between the ages of 28 and 75 years (85 421 subjects) were asked to send in a morning urine 
sample and to fill out a short questionnaire on demographics and cardiovascular history. 
A total of 40 856 subjects (47.8%) responded. After exclusion of subjects with insulin-dependent 
diabetes mellitus and pregnant women, all subjects with a urinary albumin concentration of 
>10 mg/l (n=7768), together with a randomly selected control group with a urinary albumin 
concentration of <10 mg/l (n=3395), were invited for further investigations (total n=11 163). 
Finally, 8592 subjects completed the total screening program making up the PREVEND 
study cohort. Because the PREVEND study population was enriched for albuminuria, this 
oversampling for albuminuria was counterbalanced in the current substudy. Albuminuria- 
negative participants and a random sample of albuminuria-positive participants were 
combined so that a population representative ratio of albuminuria-positive participants was 
achieved. Research assistants handed over invitations in the 2001–2002 wave to 2554 subjects 
to participate in a substudy, for which additional psychiatric and psychosocial data were 
collected. Of these 2554 subjects, 1094 (43%) completed the additional measurements.
Follow-up measurements in the 2003–2004 wave were completed by a total of 964 participants 
(89% of the cohort) with additional psychiatric and psychosocial data (see below). 
The recruitment of these participants that formed the cohort for the current study has been 
extensively described elsewhere 24. The study was approved by the local medical ethics 
committee and all subjects gave written informed consent to participate. 
Physical symptom count:
Physical symptom count was based on the somatization section of the Composite International 
Diagnostic Interview (CIDI), a fully structured psychiatric interview assessment with adequate 
test–retest reliability and validity 25. A fully computerized version of the CIDI 2.1 12-month 
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was applied, suitable for self-administration. Trained interviewers were present for questions 
and for participants who needed computer help. The probing scheme of the self-administered 
version is completely identical to the interviewer-administered version; the difference 
between both versions is that the questions are not read out loud by the interviewer but 
instead are read on the screen by the participant him/herself. 
In short, the CIDI somatization section surveys the occurrence of 43 symptoms in the past year. 
Symptoms are considered present when they meet severity criteria, i.e. provoke a healthcare 
visit. If these criteria are met, the interview assesses in a hierarchical fashion whether a 
medical doctor diagnosed a symptom as due to physical illness or injury, or whether a symptom 
was caused by the use of medication, drugs or alcohol. If these inquiries are negative for these 
medical explanations, the symptom is scored as a functional symptom. In those cases in 
which the diagnosis involved a functional syndrome (such as irritable bowel syndrome, chronic 
fatigue syndrome or fibromyalgia), the symptom was recoded as a functional symptom. 
Health related quality of life:
Self-rated health-related quality of life was measured using the descriptive section of the 
EuroQol-5 Dimensions (EQ-5D) 26. The EQ-5D  consists of a descriptive system that records 
the level of self-reported problems on each of the five dimensions of the classification (mobility, 
self-care, usual activities, pain/discomfort, anxiety/depression). For each dimension the 
respondent is asked to choose between three options: no problem, some/moderate problems, 
or extreme problems/unable. Health states defined by the five-dimensional descriptive 
system, can be converted into a weighted health state index by applying scores from value 
sets elicited from general population samples which leads to a mean weighted health index 
ranging from 0 (dead) to 1(optimal health) 27, 28. 
Covariates:
Age, sex, educational level (operationalized as the number of years of education beyond the age 
of 12), marital status (married or not married) and psychological distress (measured with the 
Dutch translation of the 12-item General Health Questionnaire [GHQ-12])29. The presence 
of depression and anxiety disorders was assessed by the corresponding sections of the CIDI 
2.1, 12 month version. For depression, all diagnoses of single or recurrent depression and 
dysthymia were included. For anxiety disorder, panic disorder with and without agoraphobia, 
social phobia and generalised anxiety disorder were included. 
Statistical analyses:
Demographics and clinical characteristics will be described for participants with and without 
MUS and/or MES as well as for older and younger patients based on an age cut-off at 65 years 9. 
Differences between groups were examined using independent samples t-tests or ANOVA 
for normally distributed, continuous variables, nonparametric Mann Whitney U tests or 
Krusskall Wallis for skewed continuous variables, and χ² tests for categorical variables. 
The impact of the number of MUS and number of MES on HRQoL was assessed with 
multiple linear regression models with HRQoL as the dependent variable and adjusted for 
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socio-demographic variables (age, sex, educational level, marital status).  In case of a significant 
interaction term between age and the number of MUS or age and the number of MES, 
analyses were separately presented for participants aged below 65 years and those aged 65 
years and older based on previous found differences in prevalence rates for MUS between 
these age groups.
In model 1, the impact of the number of MES on HRQoL was examined. In model 2, the 
impact of the number of MUS on HRQoL was examined. In model 3, the number of MES 
and number of MUS were simultaneously entered, together with their interaction. In case of 
a non-significant interaction term, the interaction term was removed from the final model. 
In order to examine the impact of psychiatric comorbidity, all models were subsequently 
adjusted for the presence of any depressive or anxiety disorder within the past 12 months. 
In case the B decreased by 10% or more after adjustment for psychiatric comorbidity, it was 
considered an explanatory factor.




For 946/964 (98.1%) of the eligible participants,  the EQ-5D and the CIDI physical symptom 
scores were available. Mean age of these participants was 55.2 (SD 11.1) years, 51.8% was 
female, and 55.5% was married. The mean number of years of education beyond the age of 
12 years was 8.1 (SD= 4.5) years. Overall, 7.1% of the participants suffered from a depressive 
disorder and 5.1% from an anxiety disorder.
Table 1 presents the characteristics separately for participants without physical symptoms, 
for participants suffering from MES, for participants suffering from MUS, and finally for 
participants suffering from both MES and MUS within the past year. MES were associated 
with older age, while MUS were not. Psychological distress differed significantly between the 
four groups, with highest levels in participants with MUS and MES, followed by those with 
MUS alone, those with MES alone, and finally lowest levels in participants without physical 
symptoms. 
The number of physical symptoms for  MUS were highest in the group of participants 
suffering from both type of symptoms. HRQoL also differed across the four groups, although 
post-hoc tests did not show any difference between persons with only MES versus those with 
only MUS. HRQoL was highest in the group with neither MUS nor MES, followed by the 
group with MUS only and MES only, whereas it was lowest in participants suffering from 
both, MES and MUS.
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Table 1. Characteristics of people with no somatic symptoms, MES, MUS or MES and MUS   
  together.
Variables No MES  MES  MUS MES Statistics
    or MUS    and MUS
   (n=284) (n=162) (n=270) (n=230) 
Socio-demographics:     
 • Age (mean (SD)) 1,3,4,6 53.1 (10.6) 57.9 (11.5) 53.7 (10.0) 57.5 (11.7) F=12, df=3, p<.001
 • Female sex (n (%)) 106 (37.3) 86 (53.1) 153 (56.7) 145 (63.0) x2=38.2 df=3, p<.001
 • Married (n (%)) 156 (54.9) 94 (58.0) 144 (53.3) 131 (57.0) x2=1.7, df=3, p=.76
 • Years education (mean  8.8 (4.5) 7.3 (4.3) 8.7 (4.5) 6.7 (4.5) F=12, df=3, p<.001
  (SD)) 1,3,4,6
Psychiatric morbidity     
 • Depressive disorder  7 (2.5) 8 (4.9) 26 (9.6) 26 (11.3) x2= 19.2, df=3, p<.001
  (n (%))
 • Anxiety disorder (n (%)) 4 (1.4) 5 (3.1) 19 (7.0) 20 (8.7) x2=17.7, df=3, p<.001
 • GHQ (mean (SD))1,2,3,4,5 0.9 (1.9) 1.8 (3.0) 2.5 (3.3) 2.7 (3.5) F=20, df=3, p<.001
Physical symptoms     
 • Number of MES n.a 1,0 (2.0)   n.a 2.0 (2.0)2.4 (2.2) x2=3.1 df=1 p=.077
  (median (IQR)) 1,3,4,5,6
 • Number of MUS n.a n.a 1.0 (1.0) 2.0 (2.0) x2=11.5, df=1, p<.001
  (median (IQR)) 2,3,4,5,6
Health related Quality of Life     
 • Dutch EQ-5D 0.95 (0.09) 0.83 (0.21) 0.84 (0.19) 0.77 (0.22) F=45, df=3, p<.001
  (mean (SD)) 1,2,3,5,6
1  Significant difference post-hoc test (p<.05) between no MES or MUS versus MES
2 Significant difference post-hoc test (p<.05) between no MES or MUS versus MUS
3 Significant difference post-hoc test (p<.05) between no MES or MUS versus MES and MUS
4 Significant difference post-hoc test (p<.05) between MES versus MUS
5 Significant difference post-hoc test (p<.05) between MES versus MES and MUS
6 Significant difference post-hoc test (p<.05) between MUS versus MES and MUS
Abbreviations: MUS, medically unexplained symptoms; MES, medically explained symptoms; p, p-value; 
GHQ, General Health Questionnaire; EQ5-D, EuroQol-5 Dimensions; n, number; SD, standard deviation; 
IQR, Interquartile Range; n.a, not applicable.
Table 2 presents characteristics of participants by age (<65 versus 65 years and over). Older 
participants were more often married, lower educated and had lower prevalence rates of anxiety 
disorders compared to their younger counterparts. The proportion of persons with MES was 
significantly higher in the older age group, as well as the mean number of MES. However, no 
differences between age groups were found for MUS in both the prevalence of participants with 
MUS as well as the mean number of MUS.
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Table 2 Comparison between participants under the age of 65, and 65 and over.
   
Variables Age <65 Age ≥65 Statistics
    (n=734) (n=212) 
Demographics:    
 • Female sex n (%) 393 (53.5) 97 (45.8) x2=4.0 df=1 p=.046
 • Years education mean (SD) 8.79 (4.46) 5.53 (3.91) t=10, df =379  p<.001
 • Married n (%) 389 (53.0) 136 (64.2) x2=8.2 df=1  p<.001
Psychiatric morbidity    
 • Depressive disorder n (%) 58 (7.9) 9 (4.2) x2=3.3 df=1 p=.068
 • Anxiety disorder n (%) 46 (6.3) 2 (0.9) x2=9.7 df=1 p=.002 
 • GHQscore mean (SD) 2.1 (3.1) 1.6 (2.7) t= 2.3  df=388 p=.019
Health related Quality of Life:    
 • Dutch EQ-5D mean (SD) .86 (.19) .84 (.19) t=1.7  df=944  p=.10
Medical symptoms    
 • One year number MES mean (SD)  .80 (1.6) 1.4 (1.8) t=-4.5 df=316 p<.001
 • One year number MUS mean (SD) 1.2 (2.0) 1.2 (1.9) t=.37 df=944  p=.75
 • Number persons with MES n (%) 270 (36.8) 122 (57.5) x2=29.2 df=1 p<.001
 • Number persons with MUS  n (%) 385 (52.5) 115 (54.2) x2=.21 df=1  p=.65
Abbreviations: MUS, medically unexplained symptoms; MES, medically explained symptoms; n,number; 
SD standard deviation. GHQ, General Health Questionnaire EQ5-D EuroQol-5 Dimensions.
Within the whole study population, linear regression analyses adjusted for socio-demographic 
characteristics, showed that the association between MUS and HRQoL was stronger 
(B=-.247; p<.001) than that between MES and HRQoL (B=-. 188; p<.001). When additionally 
adjusted for presence of depression and anxiety disorders, the strength of the association of 
MES and MUS with HRQoL became almost equal: for MES: B=-.183 (p<.001); for MUS: 
B=-.194 (p<.001). Age significantly interacted with number of MUS in explaining variance in 
HRQoL (interaction term: β=.405, t=2.7, p<.01), but not with the number of MES (Interaction 
term: β=-.14, t=-.96, p=.34).
When additionally adjusted for presence of depression and anxiety disorders, this interaction 
term remains significant for MUS  ( interaction term: β=.31, t=2.1, p=.04) and not significant 
for MES (interaction term β=-.16, t=-1.1, p=.27).  Based on the significant interaction term 
between age and MUS, analyses will be presented separately for younger and older patients.
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Table 3 Association between MES / MUS and health related quality of life by multiple linear  
  regression analysis* 
 Adjusted for socio-demographic Adjusted for socio-demographic 
 characteristics characteristics &psychopathology
    B (SE) ß p- R2 B (SE) ß p- R2 ΔB
      value    value
 Age lower than 
 65 years (n=738)         
 Model 1    .11    .23 
 • No. of MES -.229 (.028) -.29 <.001  -.211 (.026) -.27 <.001  7.9 %
 Model 2    .20    .26 
 • No. of MUS -.293 (.024) -.42 <.001  -.238 (.024) -.34 <.001  19.5 %
 Model 3**    .25    .32 
 • No. of MES -.191 (.026) -.24 <.001  -.185 (.025) -.24 <.001  3.1 %
 • No. of MUS -.272 (.023) -.39 <.001  -.220 (.023) -.32 <.001  19.1 %
 Age 65 years 
 or over (n=217)         
 Model 1    .20    .33 
 • No. of MES -227 (.044) -.34 <.001  -.194 (.041) -.29   14.5 %
 Model 2    .17    .28 
 • No. of MUS -.195 (.047) -.28 <.001  -.126 (.046) -.18 .007  35.4 %
 Model 3**    .24    .34 
 • No. of MES -.194 (.045) -.29 <.001  -.177 (.042) -.27 <.001  10.3 %
 • No. of MUS -.149 (.046) -.21 .002  -.085 (.045) -.12 .062  42.9 %
* Linear regression analyses with health related quality of life (EQ-5D) as the dependent variable and adjusted 
for age, sex, educational level, marital status; separately presented with and without adjustment for  
depression (CIDI) and anxiety (CIDI).
Abbreviations: MUS, medically unexplained symptoms; MES, medically explained symptoms; SE, standard 
error
Table 3 summarizes the associations between the health related quality of life and the number 
of MES and the number of MUS in the past 12 months for younger (age < 65 years) and older 
participants separately. 
Model 1 and 2 present the association of MES and MUS with HRQoL without additional 
adjustment for each other, whereas in model 3 both the number of MES and number of MUS 
are included. The beta’s found in model 1 and 2 hardly differ from those found in model 3, 
indicating no mutual confounding for MES and MUS. 
As indicated by the significant interaction term described above, the results in table 3 clearly 
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show that the impact of MUS on HRQoL is lower in the older age group compared to the 
younger age group, whereas no difference is noted with respect to MES. 
Overall, the effect size B for MES or MUS was reduced in each model when adjusting for the 
presence of depression and anxiety. In the younger age group, only the effect size B for MUS 
decreased with more than 10%, whereas in the older age groups the effect size B for both MES 
and MUS decreased by more than 10%. Furthermore, the explanatory effect of depression and 
anxiety in the older age groups were twice as large for MUS as compared to MES.
 
 Discussion
This study demonstrated that the impact of MUS on the HRQoL is larger than the impact of 
MES on the HRQoL and becomes nearly equal when adjusted for psychiatric co-morbidity. 
In contrast to our hypothesis, the impact of MES on HRQoL was not dependent on age, 
whereas MUS had relatively less impact on HRQoL in later life compared to younger persons. 
Interestingly, in people aged below 65 years, the impact of MUS on HRQoL is larger than the 
impact of MES, whereas opposite findings were found in the older age group. The presence 
of anxiety and depressive disorders partly explained the association between MUS and 
HRQoL and in the older age group the impact of MUS on the HRQoL even lost significance. 
In later life, comorbid affective disorders also partly explained the association between MES and 
HRQoL albeit to a lower extent. Differences between MES and MUS across age groups 
remained similar when adjusted for psychiatric co-morbidity, 
The stable prevalence rates of MUS across the lifespan we found in our study, contrast with 
many studies reporting on decreasing levels of MUS with increasing age 9, 30, 31. Nonetheless, 
the only study describing prevalence rates for MUS above the age of 65 that applied similar 
methodology by using the CIDI, reported only a mild decrease of MUS above the age of 65 32. 
Interestingly, the impact of MUS on HRQoL decreases with increasing age. This is in line with 
findings in patients with chronic pain. For example, in a Norwegian community-based study, 
older persons more often suffered from chronic pain compared to younger and middle aged 
persons, but they showed better adjustment to their pain and reported higher quality of life 
scores 33. Comparably, an outpatient clinical sample of patients suffering from non-malignant 
chronic pain showed that older patients displayed less disability and preoccupation with 
somatic symptoms, despite longer duration of pain and multiple medical illnesses compared 
to their younger counterparts 34. In a tertiary care pain clinic older patients were more likely 
to present with identifiable biomedical pathology for their chronic pain, and were less likely 
to have discernible psychological factors contributing to their complaints compared with 
younger patients 35. Several explanations may account for the decrease in impact of MUS with 
increasing age. Firstly, it could be survivor bias due to a higher mortality rate of MUS patients 
with poor HRQoL, possibly reflecting unidentified organic causes. This explanation seems 
unlikely, although data on mortality within MUS patients because of “missed organic causes” 
are scarce. In a neurological study with a 18-month follow up, missed diagnoses were found in 
0.4% 36. Moreover, mortality rates in MUS patients in a liaison psychiatry practice were even 
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lower than mortality rates in control group of patients referred for other reasons 37. Another 
explanation would be a cohort effect, in which differences between generations explain the 
reduced effect of MUS on HRQoL in older persons. For example, people that were exposed 
by World War II and less welfare in the early 20th century might have lower expectations 
of their health and well-being than the younger generations of babyboomers and following 
generations 38. Longitudinal studies are needed to examine possibly cohort effects. The fact 
that we do not see the same difference in impact of MES on HRQoL between age groups 
makes a cohort effect less likely.
Another and more plausible explanation is better adaptation and better acceptance of medical 
symptoms with increasing age. Literature focusing on the perspective of pain in the elderly 
suggests that older patients have a tendency to expect and accept pain, are more reluctant to 
complain, and have a stronger will to “keep on going”39, 40. For example, the majority of older 
people with chronic peripheral joint pain do not consult a doctor, because they see joint pain 
and stiffness as an inevitable part of ageing. They view themselves as healthy despite painful 
joints 41. Similarly, in oncology patients with comparable pain intensity and interference, older 
and younger cancer patients described different adaptations to cancer pain. Older patients 
adapted by employing accommodative strategies. Younger patients less often used such 
strategies and more often struggled with accepting the losses associated with cancer pain 42. 
Several studies have shown that better acceptance is directly related with a higher level of 
HRQoL. For example, in hemophilia-related joint pain patients, pain acceptance and HRQoL 
were correlated and increased pain acceptance was related with higher HRQoL at follow-up 43. 
Also, in people with diabetes, HRQoL was strongly related to their levels of illness acceptance 44. 
Finally, we found a large explanatory role for comorbid affective disorders in the older 
age group. This  supports the commonly  accepted view of a higher level of somatisation 
and of affective-somatic symptoms in depressed older patients compared to their younger 
counterparts 45-47. It is hard to differentiate whether these somatic symptoms originate from 
somatization or because of accentuation of symptoms of concomitant physical illness 48.  
Methodological considerations
A major strength of the present study is the large age-range, which enables the study of 
age-effects applying similar methodology. Nonetheless, for proper interpretations, some 
methodological issues should be taken into account. Firstly, generalizability of our results is 
complex. On the one hand, one may consider the attrition rate of the different recruitment 
steps in our study at least moderate. On the other hand, a population-based approach is 
valuable with respect to research on MUS and somatisation. In clinical practice, patients with 
MUS and/or somatoform disorders present in different echelons and different settings in the 
health care system, which is largely dependent on the local situation. Therefore, studies on 
clinical samples of patients with somatisation are even more difficult to generalise. Secondly, 
the prevalence of depression and anxiety disorders was low in the older age group and 
significantly lower compared to the younger age group. Therefore, the conclusion that 
depression and anxiety almost fully accounts for the variation in HRQoL of MUS in later life 
is based on the effects of depression and anxiety in a few older persons. Thirdly, we measured 
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both MUS and MES using the same instrument, enabling comparisons between both types 
of symptoms and their associations with HRQoL. The fact that MUS and MES were assessed 
with a computerized interview might be seen as a limitation. However, symptoms were only 
counted if participants had visited a medical doctor and only classified as being functional if it 
was reported that a medical doctor had indicated that all enquiries were negative for medical 
explanations. Moreover, we collected detailed information on a large number of MUS and 
performed our analyses on a continuous variable for the number of MUS instead of using an 
arbitrary cut-off score. Finally, recall bias may have attenuated the reliability of the CIDI to 
measure MUS and MES and this recall bias is likely to be associated with age 49.  We limited 
our analyses to symptoms that occurred in the last 12 months by which we have limited the 
effect of recall bias. 
Conclusion
In an adult population, the impact of MUS on HRQoL is larger than the impact of MES. This 
difference is not explained by co-morbid depression and anxiety. However, with increasing 
age the impact of MUS decreases and in older persons  becomes even lower than the effect of 
MES on HRQoL. Further research has to reveal why the impact of MUS on HRQoL decreases 
with age in contrast to the impact of MES on HRQol.
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SUMMARY AND GENERAL DISCUSSION
 Summary and general discussion
The aim of this thesis was to expand our knowledge about the presence, clinical presentation, 
and consequences of medically unexplained symptoms (MUS) in later life. Whereas for the 
adult population there is a substantive body of literature on MUS and somatoform disorders, 
studies on this subject in later life are scarce. In this final chapter, the results of previous 
chapters will be summarized and integrated, and methodological considerations will be 
discussed. Finally, implications and recommendations for intervention strategies and future 
research will be considered. 
Three main themes can be distinguished in the studies described in this thesis:  the prevalence 
of MUS and somatoform disorders in later life, the co-morbidity of MUS with depression, 
and finally the relationship between MUS and medically explained symptoms (MES). These 
themes will subsequently be outlined in this chapter, keeping in mind the key question to be 
answered in this thesis: Does age affect prevalence, clinical presentation, or impact of MUS on 
health-related quality of life (HRQoL).
 Prevalence of MUS and somatoform disorders in later life
In chapter 2, we reviewed studies on prevalence of MUS and somatoform disorders, and 
concluded that the available data suggest that prevalence rates of MUS and of somatoform 
disorders decline after the age of 65 years. Possible explanations for this decline include 
inappropriate classification models, invalid measurement instruments, a higher attribution 
of bodily symptoms to physical conditions in later life, and finally the possibility of more 
subsyndromal forms of somatoform disorders in later life.  Our findings in this thesis are in 
line with these explanations. For example, somatic symptoms in later life are believed to be 
part of the phenomenology of late life depressions 1. This might lead to lower rates of somatoform 
disorders in elderly if somatic symptoms are interpreted as reflections of depression instead of 
separately classified as MUS or a somatoform disorder. In chapter 3, we found that co-morbid 
depression was present in more than half of the patients with MUS who are referred to an old 
age psychiatric secondary care setting. Further research is needed to establish whether the 
decline of somatoform disorders in later life is indeed an effect of inadequate classification. 
In chapter 5, we showed that in about half of the older patients with MUS who visited an 
outpatient clinic for old age psychiatry, somatic pathology partly explained the severity of 
their symptoms. In younger adults with MUS, proportion of symptoms which is partially 
explained will probably be lower because of the lower burden of chronic physical diseases 2. 
In patients with comorbid chronic physical diseases, doctors and researchers are more reluctant 
to define a  somatic complaint as unexplained 3. In general, doctors in primary care are more 
likely to err symptoms as explained rather than medically unexplained, with age being the 
most important risk factor for false positive diagnosis of medically explained symptoms 4. 
Patients themselves also tend to attribute symptoms as medically explained in order to be 
taken more seriously by their general practitioner 5, 6.  When patients with a partial but not 
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sufficient somatic origin of their symptoms are excluded from a diagnosis of somatoform 
disorders, this will lead to substantial lower prevalence rates. In chapter 6, however, we found 
no effect of age on the prevalence rate of MUS within the age range from 25 to 75 years 
in a population-based cohort. The number of MUS within the last year was measured with 
the Composite International Diagnostic Interview (CIDI). We did find that the impact of 
MUS on HRQoL decreased in the later life group. Since the impact on daily functioning is an 
explicit criterion of the DSM classification system, this decreasing impact of MUS on HRQoL 
might result in lower prevalence of somatoform disorders. If true, it supports the hypothesis 
that in older persons more subsyndromal forms of somatoform disorders might exist. 
All these factors mentioned above might contribute to lower prevalence rates of MUS and 
somatoform disorders in later life.
 MUS and depression
In chapter 3, we found a high rate of co-morbid depressive mood disorders (56%) in older 
patients with somatoform disorders. Co-morbid depression was associated with a higher 
severity of the primary somatic complaint, a higher level of somatisation, and more 
functional impairments. Several limitations hamper the interpretation of these results, 
including the small size and the sampling frame of this secondary care, convenience sample, 
located at a public mental health service. Nevertheless, our findings are in line with studies 
that also revealed comorbidity rates for depression and anxiety in patients with MUS in about 
half of cases 7, 8. In primary care, reported comorbidity rates vary between 25 and 70% 3, 9, 10. 
Whether these co-morbidity rates increase with age is not clear yet. To our knowledge, 
only one study specifically addressed the issue of comorbidity by age 2. Co-morbidity rates 
between MUS and depression or anxiety did not increase with age in that study. Nonetheless, 
this study was limited to an age range from 25 to 65 years 7.
The high comorbidity with depression might be due to either an effect of depression on somatic 
symptoms, or an increase of depression due to somatic symptoms. In chapter 4, we found 
that among community-dwelling older people, pain precedes the onset of clinically relevant 
depressive symptoms whereas no effects of depression on subsequent pain were found. 
The higher incidence of depression in persons with pain was not mediated by disability, and 
remained significant when adjusted for functional limitations and number of chronic diseases. 
Patients with chronic pain thus not only have high levels of co-morbidity with depression, 
but are also at risk of developing new depressive episodes. This is especially relevant as the 
prognosis of both pain and depression worsens when both occur simultaneously 11-13.  
Is this close relation between somatic complaints and depression age specific? In chapter 6, 
we found that comorbid affective disorders explained more variance of the association 
between MUS and HRQoL in the older age group than in the younger age group. This result 
suggests that a higher level of somatisation and somatic-affective symptoms are more strongly 
associated in depressed older patients compared to their younger counterparts. More somatic 
presentation of depression in later life was demonstrated in a recent meta-analysis comparing 
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the phenomenology of major depression between older and younger adult patients 1.
The question arises whether age-related factors modify the presentation of depression or whether 
it is just a higher prevalence of co-morbid somatic illnesses that leads to more somatic symptoms 
in late-life depression. However, persistent differences in phenomenology of depression were 
also demonstrated in earlier studies after adjustment for somatic comorbidity 14, 15. Thus, aging 
appears to increase the number of somatic complaints in depression, while a high prevalence 
of depression is observed in older patients with MUS. The results in this thesis support that 
later in life, the relation between depression and somatic symptoms intensifies, leading to 
increasing diagnostic difficulties 16. 
 MUS and MES
Clearly a major difference between younger and older patients with MUS is the higher 
co-occurrence with MES in later life. Numbers of MES increase with aging due to increasing 
numbers of chronic diseases 17. When the age groups of 30-44 and above 75 years of age 
are compared, neurological and pulmonary disorders double, musculoskeletal disorders 
more than triple, hearing problems quadruple, and vision problems increase even 50-fold 2. 
The diagnostic difficulties caused by these higher numbers of MES have already been 
mentioned. In chapter 5, we identified a sufficient somatic explanation in only a small 
proportion (8%) of older patients referred for MUS, while nearly half of the formerly 
unexplained symptoms could be partially explained. There are many explanatory models for 
MUS based on biological, psychological, and social elements 18-20. In some of these models, 
biological factors are described as a precipitating factor for somatisation 21, 22.  Physiological 
changes (such as in pathophysiological processes) are then presumed to trigger a higher focus 
of attention on normal physiological sensations thus leading to MUS 23,18. However, in our 
convenience sample of older patients with MUS, a higher number of somatic diseases was 
associated with less somatisation. An explanation for this unexpected finding might be that 
more physical problems in later life might result in more adequate interpretation of bodily 
sensations and physical problems. Alternatively, older patients might simply better cope with 
bodily sensations. The findings in Chapter 6 are in line with these ideas. The number of MES 
increased with age while their impact on HRQoL remained stable. In contrast, the number of 
MUS remained stable and their impact on HRQoL decreased with higher age. This suggests 
better adaptation strategies for somatic sensations that are medically unexplained in later life. 
This is in line with other findings of relatively stable HRQoL despite increasing somatic burden 
with aging and within chronic somatic diseases 24, 25 and an increasing positive emotional 
attitude towards  physical health with increasing age 26, 27. In summary, results described in 
this thesis suggest that the higher frequency of somatic pathology influences the prevalence 
and impact of MUS in later life. Firstly, a relatively high proportion of symptoms are only 
partially unexplained due to higher levels of comorbid somatic diseases. Secondly, the impact 
of MUS on experienced HRQoL decreases in later life. 
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 What are the consequences of the new diagnostic system in DSM-5?
The validity of somatoform disorders as defined in DSM IV have been hotly debated 28-30. 
Some have even argued that somatoform disorders should be merged with depression 
or anxiety disorder categories because doubt exists about somatoform disorders as a distinct 
mental illness 31, 32. Others have argued that somatization, depression and anxiety are 
different disorders,  contributing independently to illness behaviour 21, 33. Main shortcomings 
in routine clinical care are the “mind-body dualism” based on a unreliable classification of 
complaints as medically explained or not 34, 35 and the rather random categorisation into 
different somatoform disorders 36. The used terminology of the DSM-IV is also of little use 
in primary care, because it fails to include milder forms of somatization which results in low 
rates of agreement between general practitioners diagnoses of somatization and diagnoses 
derived from DSM-IV 28, 37.  The somatic symptom workgroup for DSM-5 aimed to overcome 
these problems, and proposed major changes 29, 31, 38. In May 2013, the adaptations made in the 
DSM-5 were presented at the American Psychiatric Association congress in San Francisco. 
The chapter on somatoform disorders of the DSM has indeed been radically changed. 
Somatoform disorders as defined in DSM-IV are replaced by Somatic Symptom Disorders(SSD) 
in DSM-5 39. SSD includes the former somatisation disorder, undifferentiated somatoform 
disorder, and pain disorder. The major change in comparison with DSM IV is that the 
diagnostic criteria are no longer based on the presence of MUS, but centre around one or 
more somatic symptoms that are distressing or result in significant disruption of daily life. 
This change eliminates the diagnostic problem of distinguishing between medically explained 
and unexplained symptoms 40. Secondly, positive psychological diagnostic criteria are 
added to the diagnostic criteria. These include excessive thoughts, feelings, or behaviours 
related to the somatic symptoms or associated health concerns as manifested by at least one 
of the following: (1) Disproportionate and persistent thoughts about the seriousness of one’s 
symptoms; (2) Persistently high level of anxiety about health or symptoms; and (3) Excessive 
time and energy devoted to these symptoms or health concerns. It is assumed that inclusion of 
this positive criterion will increase the predictive validity and clinical utility of the diagnosis 41-43.
What do these changes mean for the interpretation of the studies described in this thesis, 
and for the diagnosis and care for older patients? Clearly, problems in determining whether a 
complaint is medically explained or not have become irrelevant for the diagnosis. In chapter 5, 
we showed that this diagnostic problem is especially prominent in older patients and may 
result in a large number of partially explained symptoms.  The overall agreement between 
the two geriatricians judging the main symptom as completely explained, partially explained, 
or unexplained was moderate to good, but far from perfect. Eliminating this diagnostic 
uncertainty probably increases the validity of the disorder in older persons. Higher prevalence 
rates of SSD are found in patients suffering from functional syndromes, such as fibromyalgia 
and irritable bowel syndrome, and in patients with chronic somatic diseases 44, 45. Because the 
latter are especially present in later life, it can be assumed that this will result in increasing 
numbers of SSD in older populations. Some argue that the new DSM-5 SSD increases the risk 
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of mislabelling many people as mentally ill 44, 46. When we consider the results in this thesis, 
we think that the low prevalence rates of somatoform disorders in later life are at least partly 
an artefact due to the diagnostic difficulties of the DSM-IV.  Thus, the higher prevalence of 
SSD in patients with comorbid chronic medical conditions is an improvement over DSM-IV 
diagnostic categories, because these patients were probably falsely excluded. An advantage 
of this broader scope can thus be that psychiatric assessment and treatment can be applied 
to patients who until now often stayed entangled in somatic diagnostic processes.  Studies 
show positive results for Cognitive Behavioural Treatment (CBT) for both MUS as well as 
functional syndromes like fibromyalgia and irritable bowel syndrome 47. Also mild to medium 
effect sizes for CBT are shown in patients with chronic pain and fatigue or for distress due to 
general medical conditions 48. Whether the symptoms are medically explained or not is thus 
not crucial for the effectiveness of CBT. A possible disadvantage of abandoning the concept 
of MUS may be that differences between MES and MUS are no longer noticed. Although 
the total number of symptoms is strongly correlated with impact on the HRQoL 49-51, we 
found that MUS and MES did independently correlate with HRQoL (chapter 6). Differences 
between the impact of MES and the impact of  MUS on the HRQoL were found for different 
age groups, with a lower impact of MUS but not MES on HRQoL in later life. These differences 
can lead to new insights in the process of acceptance of and adaptation to MUS, and may 
guide the development of successful treatment strategies.  
 Methodological considerations
In general, research on MUS and somatoform disorders is hampered by many methodological 
difficulties. The number of epidemiological studies is limited due to the fact that a thorough 
evaluation of both somatic and psychiatric pathology is needed for a correct classification of 
symptoms as medically unexplained. In chapter 2, we found that most of the epidemiological 
studies used a two-stage strategy to overcome this problem 3, 52-55. A screening instrument 
is administered in the wider population, followed by a more structured interview method 
for MUS in selected or high-risk populations. Data on older populations are even rarer 
because elderly are often excluded from epidemiological studies. Also in intervention studies 
focussed on somatoform disorders such as CBT and pharmacological treatment, persons 
over the age of 65 years are often excluded 56-58. Currently, no randomised controlled studies 
have been conducted among older patients suffering from MUS. Longitudinal studies in older 
cohorts also have to cope with an inevitable loss to follow-up 59. Available studies are often 
of a cross-sectional nature which hampers firm conclusions and causal interferences 60. 
The required intensive assessments for MUS result in small sample sizes in clinical studies. 
Generalisation of the results can therefore be difficult, especially since most patients with 
MUS are seen in primary care. If patients with MUS are referred to specialised care, this is 
usually to medical specialists in a general hospital rather than to psychiatrists 32. Future research 
should also concentrate on other settings, such as primary care, specialist outdoor clinics and 
geriatric outdoor settings. Another problem is that the use of different definitions for MUS 
and somatisation complicates the interpretation of the results. For example, in chapter 4 we 
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have described the longitudinal relationship between chronic pain and depression. Chronic 
pain is often mentioned in relation to unexplained symptoms 61, but surely chronic pain is 
not synonymous with MUS 62. Moreover, the definition of MUS is not strictly formulated. 
The new diagnostic category of SSD within the DSM-5 will hopefully bring more uniformity 
in definitions. Finally, the use of different instruments for measurement of somatisation is 
problematic, and none of the instruments is well-validated in older populations 63.  New 
instruments for screening and a structured interview for SSD need to be developed for or 
validated in older populations. 
 Clinical implications
In this thesis, we focused on MUS in later life. When integrating the results from the present 
thesis with the changes in the field of MUS, several clinical implications can be outlined. 
We did not find more somatization in older compared to younger age groups; on the contrary, 
prevalence rates of somatoform disorders in later life decrease. Nevertheless, special attention 
for the older age group is still required. The combined presence of MES and MUS, and 
the high prevalence of depression in this age group warrant a close collaboration between 
psychological, psychiatric, and somatic disciplines. First of all for diagnostic purposes: a 
psychiatric assessment in this high-risk population is recommended, because recognition of 
depression is hampered by a somatic presentation in primary care 16, 64. We need to realise 
that most MUS patients are not referred to psychiatrists, but receive medical investigations 
and treatments in somatic health care settings 65, 66. Therefore, prevalence rates for MUS in 
secondary care settings might be higher than in primary care 67. Multidisciplinary approaches 
are being developed for the various functional syndromes, with special outdoor clinics 
for syndromes such as chronic pain, fibromyalgia, and tinnitus 68-70. For older persons, this 
multidisciplinary approach should include a geriatric, psychiatric and psychological 
approach, which can be combined in a MUS outdoor clinic for older persons. These outdoor 
clinics can be situated within a psychiatric as well as a general hospital setting. The general 
hospital probably will be most suitable, because of lower stigmatisation for patients 71. 
This multidisciplinary approach should not be restricted to the diagnostic process. 
Instead, treatment should also intervene on somatic, psychiatric, and psychological levels 
simultaneously to optimize the level of functioning and to improve quality of life. Psychiatric 
assessment and treatment should concentrate on psychological symptoms of SSD and 
co-morbid psychiatric disorders, especially depressive disorders. In younger adults CBT is 
effective for a wide range of physical symptoms and MUS 47, 72 and pharmacological treatment 
with antidepressants are effective for MUS and various functional syndromes 73. There are no 
trials in which cognitive-behavioural therapy and antidepressants have been compared 47, 73. 
Because many MUS are partially explained by an organic cause in older patients, optimization 
of the somatic condition can also improve quality of life. For example: a patient presents 
with chronic dizziness and fear of falling started after a fall. Psychiatric evaluation might 
reveal an anxiety disorder with agoraphobia after a somatic event. Geriatric evaluation might 
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reveal low blood pressure and impaired mobility. Revision of blood pressure medication and 
physiotherapy can improve mobility and self-confidence, after which treating avoidance 
behaviour as part of CBT is more readily accepted and probably more effective. If these 
outdoor clinics are situated in secondary care, collaboration with general practitioners is crucial 
for relapse prevention in case of successfully treated patients, and to prevent iatrogenic damage 
and to support patients with partially recovered functioning or chronic MUS 74, 75. 
 Future research
To our knowledge, this thesis contains the first systematic research on medically unexplained 
symptoms in later life. Our studies have resulted in more research questions. Our review on 
prevalence rates for MUS and somatoform disorders in later life revealed that very few studies 
were available. None of the available studies focussed specifically on later life.  Thus, more 
epidemiological studies on somatisation in older populations are warranted. With the coming 
of the DSM-5, prevalence rates of SSD will be established. It will be of special interest to 
examine whether prevalence rates for DSM-5 SSD will be higher than those for DSM-IV 
somatoform disorders. Validation of measurement instruments for SSD is needed in elderly 
populations. Longitudinal studies are essential to establish the course of MUS in later life, 
their effects on incident depression, their impact on quality of life, and the associated costs. 
To date, no studies are available on the treatment of older patients with MUS. Since we 
advocated a multidisciplinary approach, we recommend to evaluate the effect of interventions 
on quality of life and well-being as outcome measurements. CBT and pharmacological 
interventions should be compared for their effectiveness in older MUS patients. Research 
on adaptive sickness cognitions in later life may be interesting, because this may feed new 
therapeutic strategies and adaptations of cognitive interventions for MUS patients in general. 
Moreover, the treatment of co-morbid somatic and psychiatric disorders should be evaluated 
and compared in condition with and without augmentation with specific treatment 
programmes for MUS. Finally, it is important to know whether a multidisciplinary approach 
can reduce total health care costs. A multidisciplinary assessment is expensive, but may 
reduce costly referrals to other secondary health care services. Another aspect that deserves 
further study is the effect of the organisation of care on treatments effectivity and health care 
costs. Such studies could compare the proposed secondary care multidisciplinary approach 
with  a collaborative care model with a focus in primary care, and even a very parsimonious 
model restricted to primary care extended with reattribution techniques, self-help groups and 
consultation letters 76-78. 
Hopefully the studies in this thesis may contribute to more attention for patients with MUS in 
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Het onderzoek in dit proefschrift is voortgekomen uit ervaringen in de klinische praktijk. 
Ouderen presenteren zich regelmatig met lichamelijke klachten zonder dat er bij uitvoerig 
lichamelijk onderzoek lichamelijke oorzaken worden gevonden die deze klachten volledig 
kunnen verklaren. Ouderen richten zich met deze klachten vaak in eerste instantie tot de 
huisarts of een somatisch georiënteerde specialist. Wanneer deze geen afwijkingen vindt, zijn 
oudere patiënten moeilijk te motiveren psychologische aspecten nader te laten onderzoeken 
door een psychiater of psycholoog. Patiënten ervaren een dergelijke doorverwijzing vaak 
als een afwijzing. Om dit probleem het hoofd te bieden is er een polikliniek opgericht voor 
onderzoek en behandeling van Somatisch Onvoldoende verklaarde Lichamelijke Klachten 
(SOLK) bij ouderen in Nijmegen waar patiënten achtereenvolgens worden gezien door 
klinisch geriater, psychiater en psycholoog. 
Onze kennis over SOLK is nagenoeg volledig gebaseerd op onderzoek bij jongere volwassenen. 
Zo weten we dat SOLK bij deze leeftijdsgroep veel voorkomen: tussen 30-50% van de klachten 
waarvoor patiënten hun huisarts bezoeken zijn klachten zonder duidelijke lichamelijke 
oorzaak.  Als de klachten aanhouden en patiënten hulp blijven zoeken, kan dat frustraties 
opleveren voor zowel patiënten als hulpverleners. Mensen met SOLK ervaren vaak een hoge 
lijdensdruk en rapporteren vaak een lage kwaliteit van leven. Tevens is er een hoge co-morbi-
diteit met depressie en angstproblemen.  In hoeverre SOLK voorkomen bij ouderen en hoe dit 
samenhangt met  de kwaliteit van leven voor ouderen is nauwelijks bekend.
In hoofdstuk 1 illustreren we drie oudere patiënten  die de specifieke problemen bij SOLK 
op latere leeftijd goed weergeven. Vermoedelijk dat juist deze specifieke problemen bijdragen 
aan de geringe aandacht voor SOLK in deze leeftijdsgroep.
Voorbeeld 1 betreft een 75 jarige vrouw met pijn aan haar benen. Diverse medisch specialisten 
vonden geen oorzaak voor haar klachten; de medische verslaglegging spreekt over “leeftijd 
gerelateerde klachten” of “slijtage”. De huisarts dacht vervolgens aan een (gemaskeerde) 
depressie, maar behandeling hierop gericht sloeg niet aan. Hierop werd zij verwezen naar 
onze polikliniek in verband met onverklaarde pijn aan haar benen. Bij aanvullend onderzoek 
door de klinisch geriater werd alsnog  een lichamelijke oorzaak gevonden, namelijk een 
vernauwing van haar wervelkanaal. Dit voorbeeld illustreert hoe moeilijk het is om verklaarde 
en onverklaarde klachten bij ouderen uit elkaar te houden. Met enige regelmaat worden 
lichamelijke klachten ten onrechte aan normale veroudering toegewezen.
Voorbeeld 2 betreft een 75-jarige vrouw met langdurige maag- en darmklachten. Zij is tevens 
bekend met recidiverende, depressieve stemmingen. Ondanks verschillende behandelingen 
door zowel een psychiater als door internist en gynaecoloog  blijven de klachten bestaan. 
Op onze polikliniek stellen we een depressieve stoornis vast. Wanneer we deze strak volgens 
de richtlijnen behandelen verbetert niet alleen haar stemming, maar verdwijnen ook haar de 
lichamelijke klachten. Dit voorbeeld geeft aan dat depressies en SOLK nauw met elkaar zijn 
verweven op latere leeftijd en soms moeilijk uit elkaar te houden zijn.
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Voorbeeld 3 betreft een 65-jarige vrouw met chronische hoofdpijn. Nadat ze publiekelijk onwel 
geworden is, is ze aanhoudend angstig  een hersentumor te hebben. Ze wordt hierdoor zo 
gehinderd, dat ze haar huis niet meer uit durft. Aanvullend onderzoek door de geriater en 
een scan van haar hoofd stelt patiënte enigszins gerust, maar de hoofdpijn blijft. Mevrouw is 
te motiveren om deel te nemen aan een psychotherapeutische groepsbehandeling om te leren 
beter met haar angst en lichamelijke klachten om te gaan. Hierop verdwijnt niet alleen haar 
angst, maar ook haar hoofdpijn. Dit voorbeeld geeft de voordelen aan van een multidisciplinaire 
aanpak door klinisch geriater, psychiater en psycholoog.
De doelstelling van dit promotieonderzoek was om meer  kennis te verwerven over het 
vóórkomen, de klinische presentatie en de gevolgen van SOLK bij ouderen. Het onderzoek 
richtte zich op de volgende deelvragen. Hoe vaak komen SOLK voor op oudere leeftijd. Wat is 
de relatie tussen SOLK en depressie. Wat is de samenhang van SOLK met medisch verklaarde 
lichamelijke klachten  en wat is de relatie  van SOLK met  de kwaliteit van leven bij ouderen.
 Voorkomen van SOLK op latere leeftijd
In hoofdstuk 2 bestudeerden we aan de hand van de bestaande literatuur hoe vaak SOLK op 
latere leeftijd voorkomen. In het meest gebruikte psychiatrische classificatiesysteem (DSM IV) 
vormen SOLK en ziekteangst de kernsymptomen van de somatoforme stoornissen. Naast de 
aanwezigheid van SOLK zijn er tevens aanvullende criteria gesteld alvorens te kunnen spreken 
van een somatoforme stoornis. Somatoforme stoornissen kunnen daarom gezien worden als 
een ernstiger vorm van SOLK en derhalve is in ons onderzoek gekeken naar het vóórkomen 
van zowel SOLK als somatoforme  stoornissen bij ouderen. De gevonden resultaten werden 
vergeleken met het vóórkomen van SOLK en somatoforme stoornissen op jongere 
leeftijden. In totaal konden we slechts 8 studies vinden die het vóórkomen van SOLK of 
somatoforme stoornissen op latere leeftijd beschreven. Er waren grote onderlinge verschillen 
tussen de diverse onderzoeken. Zo werden sommige onderzoeken uitgevoerd in de algemene 
bevolking, terwijl anderen zich richten op huisarts patiënten. Bij de diverse onderzoeken 
werden verschillende meetinstrumenten en tijdsintervallen gebruikt om het vóórkomen 
van SOLK te beschrijven. Desondanks duiden de gevonden resultaten erop dat de aantallen 
SOLK en somatoforme stoornissen stabiel zijn tot het 65e levensjaar, waarna er een afname 
plaatsvindt. Uitzondering hierop waren chronische SOLK klachten in de huisartsen praktijk. 
Deze bevindingen riepen  bij ons de vraag op of SOLK op latere leeftijd nu daadwekelijk minder 
voorkomen, of dat het een gevolg is van complexe diagnostiek op hoge leeftijd zoals geïllustreerd 
in voorbeeld 1 en 2 in hoofdstuk 1. Een andere mogelijkheid zou zijn dat op oudere leeftijd juist 
mildere vormen van aan lichamelijk symptomen gebonden stoornissen voorkomen.
 SOLK en depressie bij ouderen
In hoofdstuk 3 bekeken we een klinische steekproef van 37 achtereenvolgende patiënten 
die waren verwezen naar de polikliniek voor ouderen met SOLK in Nijmegen. Pijn bleek de 
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meest voorkomende presenterende klacht te zijn. We vonden dat veel van deze ouderen, die 
verwezen waren voor SOLK, ook last bleken te hebben van andere psychiatrische stoornissen. 
Vooral stemmingsstoornissen maar ook angststoornissen en afhankelijkheid van medicijnen 
kwamen veel voor. Bij de ouderen met SOLK die ook een depressie hadden, was er sprake 
van meer lichamelijke klachten en meer beperkingen in het dagelijks functioneren dan bij 
niet depressieve SOLK patiënten. Vanwege de sterke samenhang tussen depressie en SOLK 
hebben we in hoofdstuk 4 nader onderzocht of langdurig bestaande pijn de kans vergroot op 
het krijgen van een depressie, en vice versa of chronische depressie de kans op het optreden 
van pijn vergroot.  Dit hebben we onderzocht aan de hand van gegevens van een grote groep 
van 2028 ouderen tussen de 55 en 85 jaar bij wie over een periode van 12 jaar iedere 3 jaar 
gegevens waren verzameld over onder andere het hebben van pijn en depressieve symptomen. 
Uit de gegevens bleek dat mensen met chronische pijn een grotere kans hebben op het 
ontwikkelen van een nieuwe depressie dan mensen zonder chronische pijn.  Dit verhoogde 
risico bleef bestaan als werd gecorrigeerd voor reeds bekende factoren die ook invloed kunnen 
zijn op het ontstaan van een depressie, waaronder algemene socio-demografische variabelen 
(geslacht, opleiding en huwelijkse staat), leefstijl karakteristieken (roken, alcoholgebruik en 
lichaamsgewicht) en het voorkomen van chronische ziekten of het hebben van beperkingen 
in het dagelijks functioneren. De omgekeerde relatie, een vergrote kans op het krijgen van pijn 
in ouderen met een chronische depressie werd niet gevonden, wanneer werd gecorrigeerd 
voor reeds bekende risicofactoren voor een depressie.
 SOLK en de samenhang met medisch verklaarde 
 lichamelijke klachten bij ouderen
In hoofdstuk 5 bekeken we in hoeverre ook verklaarde lichamelijke klachten voorkomen bij 
ouderen met SOLK. In de reeds eerder genoemde steekproef van 37 oudere SOLK patiënten 
werd onderzoek gedaan naar de lichamelijke gesteldheid van deze patiënten. Hierbij werd een 
inschatting gemaakt van het aandeel van de eventueel aanwezige objectieve afwijkingen in de 
gepresenteerde klacht. Hiertoe vond bij iedere patiënt een uitgebreid en gestandaardiseerd 
onderzoek plaats door een klinisch geriater. Er werd een indeling gemaakt in volledig 
verklaarde, gedeeltelijk verklaarde of volledig onverklaarde klachten. Juist omdat dit bij ouderen 
zo moeilijk is, beoordeelde een tweede klinisch geriater onafhankelijk van de eerste geriater 
tevens de mate waarin de klacht(en) verklaard konden worden door een lichamelijke oorzaak 
aan de hand van het medisch dossier.
In 3 van de 37 patiënten werd alsnog een lichamelijke verklaring voor de klacht gevonden. 
Bij twee patiënten bestond een sterke relatie met psychosociale problemen en herstelde de 
klacht spontaan. Van de  overige 32 patiënten met SOLK bleek dat in ongeveer de helft van de 
gevallen  sprake was van lichamelijke afwijkingen die de klachten gedeeltelijk konden verklaren, 
maar niet geheel. De overeenkomst tussen de beide klinisch geriaters was redelijk goed. In 
vergelijking met ouderen met geheel onverklaarde klachten zijn ouderen met gedeeltelijk 
verklaarde klachten lichamelijk in slechtere conditie, en hebben zij meer chronische ziektes 
en meer beperkingen bij het dagelijks functioneren. Het hebben van gedeeltelijk verklaarde 
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lichamelijke klachten leidde niet tot meer lichamelijke bezorgdheid vergeleken met geheel 
onverklaarde klachten.
 SOLK en de relatie met kwaliteit van leven
In hoofdstuk 6 hebben we zowel de relatie onderzocht tussen SOLK en de kwaliteit van leven 
als tussen medisch verklaarde klachten en de kwaliteit van leven in een groep van 946 
volwassenen met een leeftijd tussen de 28 en de 75 jaar. Hierbinnen hebben we gekeken of 
deze relaties vergelijkbaar zijn bij jong-volwassenen en ouderen. SOLK bleken de kwaliteit 
van leven sterker negatief te beïnvloeden dan medisch verklaarde klachten. Als we echter 
corrigeren voor psychiatrische co-morbiditeit, die bij SOLK meer voorkomt, dan wordt de 
relatie met de kwaliteit van leven voor SOLK en verklaarde lichamelijke klachten even groot. 
Wij vonden ook dat leeftijd van invloed is op de relatie tussen SOLK en kwaliteit van leven. 
Boven de 65 jaar hangen SOLK veel minder sterk samen met de kwaliteit van leven dan bij 
jong-volwassenen. Enkel bij ouderen verdween deze relatie volledig na correctie voor de 
aanwezigheid van psychiatrische co-morbiditeit. Deze bevindingen suggereren dat ouderen 
beter om weten te gaan met SOLK dan jongere volwassenen.
 Conclusies
In hoofdstuk 7 hebben we de verschillende bevindingen uit dit proefschrift in een breder 
perspectief geplaatst en gekeken wat de verdere implicaties zijn voor de dagelijkse praktijk en 
toekomstig onderzoek. De studies in dit proefschrift hebben aangetoond dat SOLK ook op 
latere leeftijd voorkomen. De klinische presentatie en herkenning wordt gecompliceerd door 
de intensievere samenhang met depressies en door het gelijktijdig vóórkomen van medisch 
verklaarde lichamelijke klachten op latere leeftijd. De effecten van SOLK op de kwaliteit van 
leven lijken lager te zijn bij ouderen dan bij jongeren. Enerzijds kan dit wijzen op een betere 
aanpassing aan lichamelijke klachten met het stijgen van de leeftijd. Anderzijds kan het wijzen 
op het voorkomen van mildere vormen van SOLK op latere leeftijd. De studies laten verder 
zien dat een multidisciplinaire diagnostische aanpak waardevol kan zijn bij deze categorie 
patiënten. Toekomstig onderzoek moet uitwijzen of een dergelijke multidisciplinaire aanpak 
daadwerkelijk leidt tot een effectievere behandeling voor de klachten van deze patiënten 
binnen de geestelijke gezondheidszorg. Uiteraard moeten hierbij aansluitend behandelstudies 
worden uitgevoerd om psychologische- en/of medicamenteuze behandeling van SOLK bij 
ouderen te kunnen onderbouwen. Tevens zal bekeken moeten worden of een dergelijke aanpak 
kostenbesparend werkt ten opzichte van de huidige praktijk of ten opzichte van een alternatieve 
aanpak, zoals bijvoorbeeld, een vaak aanbevolen strategie van periodieke consulten door de 
huisarts om verdere medische consumptie af te remmen. 
Dit proefschrift legt de complexiteit bloot van SOLK op latere leeftijd. Hiermee willen we een 
aanzet geven voor meer aandacht voor ouderen met SOLK, zowel in de dagelijkse klinische 
praktijk als in toekomstig onderzoek. 
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daar in het begin, gezeten tussen grote stapels door ons verzamelde patiënten gegevens, nog niet 
direct naar uit. Carolien dank dat je op het goeie moment de mankracht wist op te trommelen 
om die stapels om te zetten naar datasets. Dorine dank voor het klankbord en de sparringpartner 
die je gedurende het hele traject bent geweest! Ik ben jullie zeer dankbaar en vind het ook fijn 
dat jullie mij terzijde zullen staan bij de afronding.
Mijn promotor prof dr. R. Oude Voshaar, beste Richard mijn dank voor jouw bijdrage is groot. 
Vanaf het moment dat jij aansloot bij mijn onderzoek kwam het geheel in een stroomversnelling. 
Door jouw attitude en opvatting over hoe te leren onderzoek te doen, van aanvankelijk samen 
tot uiteindelijk alleen zelf doen, kreeg ik zelf ook het geloof in dat het een haalbaar traject kon 
worden. Ook Marco wil ik bedanken voor het afstaan van de tijd met Richard, als we weer 
eens samen een avond flink aan het doorwerken waren op de computerkamer van jullie mooie 
penthouse  in Nijmegen. En Richard, hoewel je zelf een duizelingwekkend tempo hanteert in 
je eigen carrière heb ik me nooit opgejaagd gevoeld, maar steeds gestimuleerd, uitgedaagd, 
geïnspireerd en gesteund. Je benaderbare houding voor grote of kleine zaken, dat is pas bijzonder!
Mijn promotor Prof dr. J. Rosmalen, beste Judith, bedankt voor je scherpe, maar zeer 
constructieve en altijd snelle commentaar op mijn stukken. Met je kennis van onverklaarde 
lichamelijke klachten en het Groningse onderzoek vormde je een perfecte aanvulling en het kan 
geen toeval zijn dat vanaf het moment dat jij aansloot bij het traject de publicaties elkaar in rap 
tempo opvolgden.
De leden van de beoordelingscommissie, prof. dr. M. Stek, prof. dr. J. Slaets en prof. dr. S. Visser 
hartelijk dank voor het beoordelen en kritisch lezen van mijn proefschrift.
Prof dr. J. Buitelaar, prof dr. A. Speckens en prof dr. M. Olde Rikkert. Beste Jan, Anne en Marcel, 
dank dat jullie in het begin van dit traject bereid waren te luisteren naar, en structuur brachten 
in, de nog grove onderzoeks-ideeën. Ook bedankt voor jullie soepele opstelling toen gedurende 
het traject dingen toch anders gingen lopen. Speciale dank Marcel voor je hulp bij het zetten van 




Al mijn co-auteurs wil ik bedanken voor hun bijdrages, commentaren en soms ook het mogen 
gebruiken van bestaande datasets. Rose Collard, Rose bedankt dat je me hebt geholpen verder 
wegwijs te worden met SPSS zodat ik de bij de cursus opgedane kennis direct met feedback kon 
toepassen, dank voor je geduld en altijd snelle reacties.
Prof dr. Aartjan Beekman wil ik danken voor het gebruik van de data van het LASA onderzoek 
en je interesse in het onderzoek. Je houding was steeds zeer coöperatief en gericht om optimaal 
gebruik te maken van de nog verborgen bevindingen in deze opgeslagen datasets. 
Directie en afdeling ProCES van Pro Persona wil ik danken voor het faciliteren van het doen 
van onderzoek naast mijn klinische bezigheden door het toekennen van onderzoekuren. Verder 
mijn leidinggevenden gedurende de afgelopen jaren, met name Jan van Haandel, Rene van de 
Water en Maarten Meulbroek. Jullie waren altijd bereid mee te denken en te luisteren als er een 
plan kwam om de patiëntenzorg te veranderen. Zoals bij het opzetten van een poli voor ouderen 
met Onverklaarde Lichamelijke Klachten. Jullie hielpen dit vorm te geven en te ondersteunen 
met secretaresses, doktersassistente etc. Hartelijke dank, ondanks mijn gemopper soms over 
krapte in bezettingen. 
Overige medewerkers en collega’s van ProPersona zoals alle secretaresses die voor mij lijsten 
met gegevens moesten verzamelen, arts-assistenten die hielpen gegevens te bewerken, collega’s 
die tijdens mijn onderzoekuren niet op mij konden terugvallen en altijd geïnteresseerd bleven 
vragen hoe ver het stond met mijn onderzoek. 
Mijn vrienden Rolf Blankemeijer en Jan-Willem de Klein; Rolf je hebt onbedoeld mede de aanzet 
gegeven tot het doen van dit promotieonderzoek. Door je altijd prikkelende stellingen zag ik 
in wat een voorrecht het is om tijd aan onderzoek te kunnen besteden en je begrijpt dat ik nu 
dus wacht op jouw proefschrift. Jan-Willem samen doelen stellen om naar toe te werken was 
stimulerend. Ik vrees wel dat de in het vooruitzicht gestelde sabbatical en bijbehorende reis als 
beloning voor onze trajecten nog even op zich zal laten wachten. Maar we kunnen vast wel een 
goede plaats vinden om eens te proosten op de goede afloop van beide trajecten, wellicht in 
Dublin? Richard van Driel, wat een heerlijk gevoel dat ik volledig op jou kon vertrouwen voor 
de vormgeving van dit proefschrift.
Marianne sinds jij in mijn leven bent gekomen heb ik voor alles meer energie gekregen en dat 
heeft ook zeker gegolden voor dit proefschrift. Waar sommigen vreesden dat door mijn privé 
beslommeringen het schip zou stranden, voelde ik juist volle wind in de zeilen en hernieuwde 
energie om mijn doel te bereiken, zeker ook door jouw aanmoedigingen om door te zetten. 
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Medically unexplained symptoms in later life
1. Dat de prevalentie van Somatisch Onvoldoende verklaarde Lichamelijke Klachten (SOLK) 
 na het 65e jaar afneemt komt ten dele doordat lichamelijke klachten op latere leeftijd 
 eerder worden toegeschreven aan een co-morbide depressie of somatische aandoening 
 (dit proefschrift).
2. Bij een oudere die zich presenteert met een chronisch onverklaarde lichamelijke klacht  is 
 een verhoogde alertheid op aanwezigheid van psychiatrische stoornissen noodzakelijk 
 (dit  proefschrift).
3. Zowel een goed psychiatrisch onderzoek alsook een gedegen evaluatie door een klinisch 
 geriater draagt bij tot betere zorg voor ouderen met persisterende SOLK (dit proefschrift).
4. Chronische pijn bij ouderen leidt tot verhoogde kans op het krijgen van een nieuwe 
 depressieve episode (dit proefschrift).
5. Een mindere impact van SOLK op de kwaliteit van leven bij ouderen in vergelijking met 
 jongere volwassenen zou kunnen betekenen dat ouderen zich beter kunnen aanpassen aan 
 het krijgen van lichamelijke klachten (dit proefschrift). 
6. Onverklaard maakt onbemind.  
7. De gezondheid van de patiënt is vaak omgekeerd evenredig met het aantal dokters betrokken 
 bij zijn behandeling.
8. Een goed hoofd en een goed hart vormen altijd een geweldige combinatie (Nelson Mandela).
9. Het gaat om de reis, niet om de bestemming (Confusius).
STELLINGEN BEHORENDE BIJ HET PROEFSCHRIFT
